Effect of porcine sheath proteins on the regeneration activity of periodontal ligament

ABSTRACT

The purpose of this study was to identify the periodontal regeneration factors in enamel protein shown to induce cementum- and osteo-promotive activities in vivo. The cementum regeneration (CR), a part of periodontal regeneration, was examined by using experimental cavities prepared in a buccal dehiscence dog model. The CR activity was found in the aggregate consisted of sheath proteins along with a small amount of amelogenins separated from newly formed secretory enamel. The sheath proteins were purified to be homogeneous, and examined for the alkaline phosphatase (ALP) inducing activity of human periodontal ligament (HPDL) cells. Application of 17 kDa sheath protein induced ALP activity in HPDL cells. Peptides synthesized from the sheath protein sequence also showed ALP inducing activity. The 17 kDa sheath protein has cell differentiation activity.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority upon U.S. Provisional Patentapplication Ser. No. 60/669,670 filed on Apr. 9, 2005, the contents ofwhich are all herein incorporated by this reference in their entireties.All publications, patents, patent applications, databases and otherreferences cited in this application, all related applicationsreferenced herein, and all references cited therein, are incorporated byreference in their entirety as if restated here in full and as if eachindividual publication, patent, patent application, database or otherreference were specifically and individually indicated to beincorporated by reference.

REFERENCE TO A SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM LISTINGCOMPACT DISC APPENDIX

This application refers to protein sequences by SEQ ID number. Thesesequences are listed below and are contained in the file“fukae-bio-seq.txt” (13 KB, created on Jun. 26, 2006), which is herebyincorporated in its entirety herein.

BACKGROUND OF INVENTION

1. Field of the Invention

The present invention relates generally to the field of periodontaltissue regeneration, and particularly concerns the treatment of diseasesrelated to periodontitis and periodontal disease. The invention provides17 kDa sheath protein and its derived peptides, which have cementumregeneration promoting activity and are involved in periodontalregeneration and cytodifferentiation of periodontal ligament cells. Alsodisclosed are the methods for isolating other enamel matrix proteins,and various therapeutic methods using the compositions of the invention.

The invention provides a cementum regeneration promoting protein segmentcomprising an isolated, synthesized and recombinant sheath protein,polypeptide, or peptide. In certain embodiments of the presentinvention, the sheath protein is a porcine sheath protein. In otherembodiments of the present invention the sheath protein is a human,murine, rat, bovine, sheep, monkey and every mammal sheath protein.

As used herein in the context of various of the instant compositions andmethods, the term “protein” will be understood to mean a proteinaceoussegment that is longer than about 150 contiguous amino acids and in mostaspects comprises more than about 70% of the amino acids encoded by agene. As used herein in the context of various of the instantcompositions and methods, the term “polypeptide” will be understood tomean a proteinaceous segment that is longer than about 50 contiguousamino acids in length, and the term “peptide” will be understood to meana proteinaceous segment that is between about 3 and about 50 contiguousamino acids in length. Thus sheath protein proteinaceous segment ofvarying overall length that retain signaling, regulatory and structuralproperties and functions are provided herein.

As used herein in the context of various of the instant compositions andmethods, the term “sheath protein” or the term “sheathlin” will beunderstood to include wild-type, polymorphic and mutant versions ofsheath protein or sheathlin sequences. Wild-type sequences are definedas the first identified sequence; polymorphic sequences are defined asnaturally occurring variants of the wild type sequence that have noeffect on the expression or function of the sheath protein or sheathlinproteins, polypeptides, or peptides or domain thereof; and mutantsequences are defined as changes in the wild-type sequence, eithernaturally occurring or introduced by the hand of man, that have aneffect on either the expression and/or the function of the sheathprotein or sheathlin proteins, polypeptides or peptides or domainsthereof. The invention thus also includes the provision of DNA segmentsvectors, genes and coding sequence region that encode various forms ofsheath protein or sheathlin proteins, polypeptides, peptides or anyfusion protein, polypeptides or peptide thereof.

As used herein in the context of various of the instant compositions andmethods, the term “cementum regeneration promoting protein” will beunderstood to include the proteins, polypeptides and peptides containingamino acid sequences shown a cementum regeneration promoting activity insheath protein sequences. Wild-type sequences are defined as the firstidentified sequence; polymorphic sequences are defined as naturallyoccurring variants of the wild type sequence that have no effect on theexpression or function of the sheath proteins, polypeptides, or peptidesor domain thereof; and mutant sequences are defined as changes in thewild-type sequence, either naturally occurring or introduced by the handof man, that have an effect on either the expression and/or the functionof the sheath proteins, polypeptides or peptides or domains thereof. Theinvention thus also includes the provision of DNA segments vectors,genes and coding sequence region that encode various forms of sheathproteins, polypeptides, peptides or any fusion protein, polypeptides orpeptide thereof.

The sheathlin (Hu et al., 1997a) is the parent protein of sheath protein(Uchida et al., 1995) which is named as it is accumulated to the enamelsheath of immature enamel to reveal honeycomb pattern onimmunohistochemical detection. The sheath protein is firstly found to be13 kDa˜17 kDa non-amelogenin protein in newly formed enamel of pig(Fukae and Tanabe, 1987a). The sheathlin is degraded at early stage ofdevelopment into three peptides, 17 kDa sheath protein, 25 kDa acidicprotein and Ca binding protein (Fuake and Tanabe, 1987b).

Various therapeutic methods using the compositions of the inventioncontains the application for not only periodontal ligament regeneration,cementum regeneration and alveolar bone regeneration against periodontaldisease and periodontitis, but also implant of artificial material liketooth and replantation of extracted tooth.

2. Description of Related Art

The enamel matrix proteins (enamel matrix derivatives: EMD) are used forrepairing the periodontal ligament of periodontitis as one of theperiodontal regeneration remedy. It is well accepted that the enamelmatrix proteins have the periodontal regeneration activity (Hammarström1997, Hammarström et al., 1997). Nevertheless, the final periodontalregeneration which gratifies patient's desires is not alwaysaccomplished. In addition there is a risk of infection of E type orunknown virus, since the extract from porcine immature enamel matrix isused for the remedy for clinical treatment, although the risk is atpresent avoided by heating the enamel matrix proteins before preparingthe remedy. Another risk is that immunity from EMD for repeatapplication to the same patient is not always denied, although clinicalsafety of EMD is reported (Zetterström et al., 1997). The biggestproblem is at present scarce information about periodontal regenerationpromoting factor, because the enamel matrix proteins are consisted ofmulti components.

Enamel Matrix Proteins

There are in the enamel matrix three enamel matrix proteins and twoproteolytic enzymes. The cDNA and derived amino acid sequences of theseproteins and proteinases have been revealed by previous studies. Inaddition, two growth factors are found to be in porcine secretory enamelmatrix.

The structural proteins are amelogenin, (Fukae et al., 1983; Snead etal., 1985; Shimokawa et al., 1987), enemelin (Fukae et al., 1993; Fukaeet al., 1996; Hu et al., 1997b), and sheathlin (ameloblastin/amelin)(Cerny et al., 1996; Krebsbach et al., 1996; Hu et al., 1997a). In thedeveloping enamel matrix, enamel matrix serine proteinase (EMSP) (Fukaeet al., 1977; Tanabe 1983; Tanabe et al., 1996; Simmer et al., 1998) anda novel metalloproteinase (enamelysin) (Bartlett et al., 1996; Fukae etal., 1998) are cloned and characterized. It is confirmed in porcineenamel matrix the existence of osteogenetic growth factors which arebone morphogenetic factor (BMP) and transforming growth factor (TGF)-β(Suzuki et al., 2005).

Therefore, the immature enamel matrices throughout several developingstages contain a lot of amelogenin, sheathlin and enamelin derivatives.If the purification of specific protein was performed from enamel matrixprotein fraction, the purification is interrupted by the causes of a lotof amelogenin gene products and their derivatives, and their aggregationnature.

Amelogenin

Amelogenins are abundant throughout the developing enamel matrix, andhave an aggregation nature in solution. They aggregate to form aprecipitate in neutral pH at room temperature and reversibly changetheir phase into the solution at lower temperature. Protein chemicalanalyses suggest that apparent molecular weights of 25 kDa amelogenin,one of uncleaved amelogenin polypeptides (Fukae et al., 1980; Uchida etal., 1991) is most abundant in the porcine gene products along with 27,18 and 6.5 kDa amelogenins produced by splicing of amelogenin mRNA(Yamakoshi et al., 1994; Hu et al., 1996; Ikawa et al., 2005).

In newly formed enamel porcine 25 kDa amelogenin is converted by thecleavage of C-terminal hydrophilic domain with the action of enamelysininto 20 kDa amelogenin, and then in advanced developmental secretoryenamel the 20 kDa amelogenin is splitted out into two fragments of 6 kDaand 13 kDa amelogenins by the action of the other proteinase EMSP(KLK4). The 13 kDa amelogenin is soluble in neutral solution anddisappears from the system to produce the space for crystal growthduring the secretory stage enamel.

Sheathlin

Sheathlin has 65 kDa molecular mass and is the parent protein of sheathprotein which is named for 13˜17 kDa non-amelogenin protein foundfirstly in porcine newly formed enamel matrix (Fukae and Tanabe 1987a;Uchida et al., 1991). Porcine sheathlin is degraded at once after itssecretion from ameloblasts into three segments, 17 kDa sheath proteinderived from N-terminal side, 29 kDa calcium binding protein derivedfrom C-terminal side (Fukae and Tanabe 1987b; Murakami et al., 1997;Yamakoshi et al., 2001) and 25 kDa acidic protein derived from middlepart of molecule. The sheath protein accumulates at once to in futureprism sheath space (Uchida et al., 1991; Uchida et al., 1995) and isdegraded into lower molecular weight of 15 kDa and 13 kDa sheath proteinin advanced developing stage of secretory enamel.

Enamelin

Enamelin is a parent protein of 155 kDa with cleavage products havingapparent molecular weights of 142, 89, 56, 45, 34, 32, and 25 kDa (Fukaeet al., 1996; Hu et al., 1997b). In the newly formed enamel 89 kDaenamelin is mainly existed in alkaline soluble fraction. In advanceddeveloping secretory enamel the 89 kDa enamelin is degradated into 32kDa enamelin which is soluble in neutral solution and has affinities forfluorohydroxyapatite (Tanabe et al., 1990) and Ca ions (Yamakoshi etal., 2001).

Growth Factors

There is additional evidence that, besides enamel proteins, potentsignaling molecules may be resident in enamel extracts. Recently, bonemorphogenetic protein (BMP)-like activity was deduced to be in porcineenamel extracts using ST2 cells (a mouse bone marrow stromal cell line)by the action of noggin (Iwata et al., 2002), transforming growth factorbeta (TGF-β)-like activity was identified using oral epithelial andfibroblastic cells (Kawase et al., 2001). The TGF-β-like activity in theenamel matrix protein increases the ALP activity of HPDL cells, promotestheir cytodifferentiation, and finally induces mineralization (Nagano2003). The relationship between the presence of these growth factor-likeactivities in enamel extracts and the induction of osteogenesis andcementogenesis during periodontal regeneration is unknown.

It is shown that the periodontal ligament (PDL) is regenerated in theexperimental cavities of intrabony defects created on a buccaldehiscence model in monkeys after the application of porcine enamelmatrix proteins (Hammarström 1997, Hammarström et al., 1997). The ideathat enamel matrix proteins are involved in the formation of cementum isbased on the fact that coronal acellular extrinsic fiber cementum isformed on enamel surface in a number of species (Hammarström 1997).Application of porcine enamel matrix in experimental cavities in theroots of incisors of monkeys induces formation of acellular cementumthat is well attached to the dentin. It indicates the enamel matrixproteins have the potential to induce regeneration of the same type ofcementum (Hammarström 1997, Hammarström et al., 1997). The enamel matrixderivatives stimulate the proliferation and differentiation of human PDLcells (Gestrelius et al., 1997) and enhance bone formation (Boyan etal., 2000). These show that enamel proteins have bioactivities such asthe induction of osteogenesis and cementogenesis.

Based on these results, the enamel proteins, enamel matrix derivatives(EMD) which is commercially available as EMDOGAIN®, are used clinicallyfor PDL regeneration of periodontitis (Heijl 1997, Heijl et al., 1997).This new treatment induces a noteworthy result which is not obtained upto that time as the effect of periodontal disease treatment. However,when the enamel proteins are used for the treatment of periodontitis,periodontal ligament regeneration is not always accomplished to thelevel of expected result. It indicates that the usage of enamel proteinsfor the treatment of periodontal disease leaves much room forimprovement.

The problem remaining to be solved is the elucidation of the real formof bioactivities contained in the enamel proteins. The researchersdeveloped the EMD expect that the bioactivities are due to theamelogenin family a major component in enamel matrix. However, this ideais denied by finding the existence of periodontal ligament inamelogenin-deficient mice (Gibson et al., 2001). In fact, theamelogenins and their derivatives separated by ammonium sulfateprecipitation fractionation (Kanazashi et al., 2004) or gel filtrationsystem (Kanazashi et al., 2006; Fukae et al., 2006) have no cementumregeneration activity by histological analyses using experimentaldefects created on buccal dehiscence model of dogs.

There is another approach to estimate the bioactivities such asosteoinductive activities, BMP-like activity (Iwata et al., 2002) andTGF-β-like activity (Kawase et al., 2001). The TGF-β-like activity inthe enamel matrix protein increases the alkaline phosphatase (ALP)activity of human periodontal ligament (HPDL) cells, promotes their celldifferentiation and finally induces the mineralization (Nagano 2003;Nagano et al., 2004). The existences of both BMP and TGF-β in porcineenamel proteins are confirmed by lucipherase reporter assays (Suzuki etal., 2005). However, it is unclear the function of these osteoinductivefactors in periodontal regeneration in in vivo system, although thesemay contribute to the induction of osteogenesis and cementogenesis orboth and biomineralization during periodontal regeneration.

It is not doubted that the EMD has the periodontal regenerationactivity. However, it is too hard to separate the activity from the EMDsince the EMD consists of multi components containing a lot ofamelogenins and their derivatives which have aggregation nature. Toavoid the obstruction by amelogenin aggregation, the usage of newlyformed secretory enamel for separating the cementum regenerationpromoting factor seems to be advantageous. Because it contains thesmallest amount of amelogenin degradation products comparing to theother advanced developmental immature enamel. The 0.05M carbonate buffer(pH 10.8) which inhibits the aggregation of amelogenins is employed forthe separation. Over 95% of whole proteins contained in immature enamelis solubilized briefly by homogenizing in this buffer (Fukae and Tanabe,1998).

The management to avoid the degradation of periodontal regenerationactivity is employed. There are at least four proteolytic activitiesdetected in developing dental enamel matrix. They are twometalloproteinases, gelatinase and enamelysin (MMP-20) (Bartlett et al.,1996; Fukae et al., 1998), and two serine proteinases including EMSP(KLK4) (Fukae et al., 1977; Shimizu et al., 1979; Simmer et al., 1998).Enamel matrix serine proteinase and enamelysin were cloned characterizedand involved in the degradation of amelogenins and non-amelogeninproteins during not only transition stage enamel but also secretorystage enamel (Tanabe et al., 1992; Tanabe et al., 1996; Fukae andTanabe, 1998). EMSP and proEMSP found in the secretory enamel areextracted with only the neutral phosphate buffer. The extraction ofneutral soluble fraction is needed to avoid the degradation ofperiodontal regeneration activity, since proEMSP is activated withmetalloproteinases (Tanabe et al., 1996). The action of MMP-20 found inalkaline soluble fraction was inhibited by adding at once EDTA, theinhibitor of matrix metalloproteinase, after the extraction of alkalinesoluble fraction.

Complete periodontal regeneration could be accomplished by firstcementum regeneration (CR) along with burying of collagenous bundles andthen periodontal ligament regeneration and alveolar bone regeneration,if it is reasoned by the analogy of root formation at tooth development.Therefore, the cementum regeneration is thought to be most importantpart in the periodontal regeneration processes. Nevertheless, since nomarker protein is found in the cementum formation, the histologicalanalysis on buccal dehiscence model of dogs are employed for cementumregeneration (CR) activity of fractionated enamel proteins. The CRcapacity of individual protein fraction obtained at each separation orpurification step is evaluated step by step by the regenerated cementumof eight weeks produced on the experimental intrabony defects createdalong the roots of the canine mandibular premolars.

When porcine enamel proteins are separated under the difference ofdevelopmental stage and examined for their CR activity, the CR activityis found in newly formed enamel rather than the advanced developmentalsecretory enamel. In newly formed secretory enamel, CR activity wasdetected in the alkaline soluble fraction, but not in the neutralsoluble fraction. When the alkaline soluble fraction was separated into4 fractions by Sephadex G-100 gel filtration, CR activity was found inthe first eluted peak (fraction 1) containing the aggregate of sheathproteins along with a small amount of amelogenins and enamelins. Theother peaks consisted of amelogenins and their derivatives had no CRactivity.

When the fraction 1 was separated into enamelin fraction and aggregatefraction containing sheath proteins and amelogenins, the activity wasfound in the aggregate fraction. It is concluded the CR activity was insheath proteins, because the amelogenin had no CR activity. And sosheath proteins were purified in dissociative condition and homogeneousprotein fraction of each 13 kDa, 15 kDa and 17 kDa sheath protein wasobtained. CR activity was found only in 17 kDa sheath protein. The 17kDa sheath protein was split into 15 kDa sheath protein by the cleavageof C-terminal side peptide and the 13 kDa sheath protein was derivedfrom the 15 kDa sheath protein by the cleavage of N-terminal sidepeptide. Therefore, CR activity was existed in the sequence ofC-terminal side of 17 kDa sheath protein.

After CR activity was determined to be resided in the C-terminal peptideof 17 kDa sheath protein, to search the specific sequence having CRactivity was examined by the detection of alkaline phosphatase inducingactivity of human periodontal ligament (HPDL) cells, after applicationof purified enamel proteins or their peptides on cell culture system.The employment of cell culture system is handy method to link thedetection of CR promoting activity, because the increase of ALP activityof HPDL cells shown their cytodifferentiation plays important functionfor acellular cementum formation, deduced from morphometric evaluationin the light microscope on ALP-deficient mice (Beertsen et al., 1999).In general, it is unclear whether the evaluation of ALP activity in HPDLcell culture system contributes to the induction of osteogenesis orcementogenesis. However, CR activity resided in the 17 kDa sheathprotein was determined by the regenerated cementum of eight weeksproduced on the experimental intrabony defects created on the caninemandibular premolars' roots. Therefore, the increase of ALP activity ofHPDL cells in the cell culture system links strongly to the evaluationof CR promoting activity of 17 kDa sheath protein or peptides. It wascharacterized about HPDL cells on cell culture system that ALP activityof HPDL cells induced by adding 1α-25-dihydroxy-Vitamin D₃ was increasedby adding TGF-β, and decreased by adding BMP

The purified porcine three sheath proteins were examined their ALPinducing activity of HPDL cells in cell culture system. ALP inducingactivity was found in 17 kDa sheath protein, but scarce activity was in13 kDa and 15 kDa sheath proteins. It indicates the cytodifferentiationactivity of HPDL cells is resided in the C-terminal side peptide of 17kDa sheath protein. And so, based on the sequence of porcine or humansheath protein, the peptides were synthesized and examined their ALPinducing activity on the cell culture system. On human synthesizedpeptides, SEQ ID NO: 1 and SEQ ID NO: 2 were shown dose dependently toincrease ALP inducing activity of HPDL cells. Since the activities ofthese peptides were not inhibited by TGF-β1 inhibitor, TGF-β1 receptorwas not common receptor of these peptides.

As will be appreciated by persons skilled in the art, the invention alsorelates to protein sequences with deduced amino acid sequences of SEQ IDNO:1 to SEQ ID NO:34 which have preferably 5% or greater identity, morepreferably 10% or greater identity, more preferably 15% or greateridentity, more preferably 20% or greater identity, more preferably 25%or greater identity, more preferably 30% or greater identity, morepreferably 35% or greater identity, more preferably 40% or greateridentity, more preferably 45% or greater identity, more preferably 50%or greater identity, more preferably 55% or greater identity, morepreferably 60% or greater identity, more preferably 65% or greateridentity, more preferably 70% or greater identity, more preferably 75%or greater identity, more preferably 80% or greater identity, morepreferably 85% or greater identity, more preferably 90% or greateridentity, more preferably 95% or greater identity, more preferably 96%or greater identity, more preferably 97% or greater identity, morepreferably 98% or greater identity, and more preferably 99% or greateridentity.

The present invention further provides proteins that consist essentiallyof the amino acid sequences provided in SEQ ID NO:1 to SEQ ID NO: 34. Aprotein consists essentially of an amino acid sequence when such anamino acid sequence is present with only a few additional amino acidresidues, for example from about 1 to about 100 or so additionalresidues, typically from 1 to about 20 additional residues in the finalprotein.

The present invention further provides proteins that comprise the aminoacid sequences provided in SEQ ID NO: 1 to SEQ ID NO: 34. A proteincomprises an amino acid sequence when the amino acid sequence is atleast part of the final amino acid sequence of the protein. In such afashion, the protein can be only the peptide or have additional aminoacid molecules, such as amino acid residues (contiguous encodedsequence) that are naturally associated with it or heterogeneous aminoacid residues/peptide sequences. Such a protein can have a fewadditional amino acid residues or can comprise several hundred or moreadditional amino acids.

To determine the percent identity of two amino acid sequences, thesequences are aligned for optimal comparison purposes (e.g., gaps can beintroduced in one or both of a first and a second amino acid sequencefor optimal alignment and non-homologous sequences can be disregardedfor comparison purposes). In a preferred embodiment, at least 30%, 40%,50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequenceis aligned for comparison purposes. The amino acid residues atcorresponding amino acid positions are then compared. When a position inthe first sequence is occupied by the same amino acid residue as thecorresponding position in the second sequence, then the molecules areidentical at that position (as used herein amino acid “identity” isequivalent to amino acid “homology”). The percent identity between thetwo sequences is a function of the number of identical positions sharedby the sequences, taking into account the number of gaps, and the lengthof each gap, which need to be introduced for optimal alignment of thetwo sequences.

Some embodiments of the present inventions are described with referenceto the numbered paragraphs below:

1. A protein comprising: an isolated sheath protein that is one of aderivative produced by the action of proteinase from a sheathlin(ameloblastin/amelin), one of structural enamel proteins; and is derivedfrom amino-terminal side of the sheathlin.

2. The protein of paragraph 1, where the isolated sheath protein ismammalian.

3. The protein of paragraph 2, where the isolated mammalian sheathprotein is porcine.

4. The protein of paragraph 2, where the isolated mammalian sheathprotein is human.

5. The protein of paragraph 1, where amino acid sequence of the isolatedsheath protein is selected from the group consisting of SEQ ID NO: 10and SEQ ID NO: 11.

6. A method of producing an effect comprising administering the proteinof paragraph 5 to a mammal.

7. The method of paragraph 6, where the mammal is a Human.

8. A method of producing an effect comprising administering the proteinof SEQ ID NO: 11 to a mammal.

9. The method of paragraph 8, where the mammal is a Human.

10. A polypeptide or peptide segment characterized as: comprising asequence region of at least about 3 contiguous amino acids that have thesame sequence as about 3 contiguous amino acids of the sequence selectedfrom the group consisting of SEQ ID NO: 12 and SEQ ID NO: 13; orcomprising from 3 to about 1,000 amino acids in length that synthesizesthe polypeptide segment selected from the group consisting of SEQ ID NO:12 and SEQ ID NO: 13.

11. The polypeptide or peptide segment of paragraph 10, wherein thesegment comprises a sequence region of at least 3 contiguous amino acidsof the sequence selected from the group consisting of SEQ ID NO: 12 andSEQ ID NO:13.

12. The polypeptide or peptide segment of paragraph 10, wherein thesegment is from about 3 to about 1,000 amino acids in length andsynthesizes an amino acid segment of an artificial sequence comprising asequence region of contiguous amino acids of the sequence selected fromthe group consisting of SEQ ID NO: 12 and SEQ ID NO: 13.

13. The polypeptide or peptide segment of paragraph 10, wherein thesegment is from about 3 to about 1,000 amino acids in length andbiosynthesizes by a recombinant protein expression system to the aminoacid segment of an artificial sequence comprising a sequence region ofcontiguous amino acids of the sequence selected from the groupconsisting of SEQ ID NO: 12 and SEQ ID NO: 13.

14. A method of producing an effect comprising administering the proteinof paragraph 10 to a mammal.

15. The method of paragraph 14, where the mammal is a Human.

16. A polypeptide or peptide segment characterized as: comprising asequence region of at least about 3 contiguous amino acids that have thesame sequence as about 3 contiguous amino acids of the sequence selectedfrom the group consisting of SEQ ID NO: 24 and SEQ ID NO: 25; orcomprising from 3 to about 1,000 amino acids in length that synthesizesthe polypeptide segment selected from the group consisting of SEQ ID NO:24 and SEQ ID NO: 25.

17. The polypeptide or peptide segment of paragraph 16, wherein thesegment comprises a sequence region of at least 3 contiguous amino acidsof the sequence selected from the group consisting of SEQ ID NO: 24 andSEQ ID NO: 25.

18 The polypeptide or peptide segment of paragraph 16, wherein thesegment is from about 3 to about 1,000 amino acids in length andsynthesizes an amino acid segment of an artificial sequence comprising asequence region of contiguous amino acids of the sequence selected fromthe group consisting of SEQ ID NO: 24 and SEQ ID NO: 25.

19. The polypeptide or peptide segment of paragraph 16, wherein thesegment is from about 3 to about 1,000 amino acids in length andbiosynthesizes by a recombinant protein expression system to the aminoacid segment of an artificial sequence comprising a sequence region ofcontiguous amino acids of the sequence selected from the groupconsisting of SEQ ID NO: 24 and SEQ ID NO: 25.

20. A method of producing an effect comprising administering the proteinof paragraph 16 to a mammal.

21. The method of paragraph 20, where the mammal is a Human.

22. A polypeptide or peptide segment characterized as: comprising asequence region of at least about 3 contiguous amino acids that have thesame sequence as about 3 contiguous amino acids of SEQ ID NO: 9; orcomprising from 3 to about 1,000 amino acids in length that synthesizesthe polypeptide segment of SEQ ID NO: 9.

23. The polypeptide or peptide segment of paragraph 22, wherein thesegment comprises a sequence region of at least 3 contiguous amino acidsfrom SEQ ID NO: 9.

24. The polypeptide or peptide segment of paragraph 22, wherein thesegment is from about 3 to about 1,000 amino acids in length andsynthesizes an amino acid segment of an artificial sequence comprising asequence region of contiguous amino acids from SEQ ID NO: 9.

25. The polypeptide or peptide segment of paragraph 22, wherein thesegment is from about 3 to about 1,000 amino acids in length andbiosynthesizes by a recombinant protein expression system an amino acidsegment of an artificial sequence comprising a sequence region ofcontiguous amino acids from SEQ ID NO: 9.

26. A method of producing an effect comprising administering the proteinof paragraph 22 to a mammal.

27. The method of paragraph 26, where the mammal is a Human.

28. A polypeptide or peptide segment characterized as comprising asequence region selected from the group consisting of SEQ ID NO: 1, SEQID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ IDNO: 7, and SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28,SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO: 32.

29. A method of producing an effect comprising administering thepolypeptide segment of paragraph 28 to a mammal.

30. The method of paragraph 28, where the mammal is a Human.

31. A composition comprising an isolated aggregate that comprises asheath protein.

32. The composition of paragraph 31, where the isolated aggregate formswith sheath proteins and amelogenins in an alkaline solution.

33. The composition of paragraph 31, where the isolated aggregateresides in outer layer enamel, newly formed enamel, corresponding toapproximately 30 μm thickness from the surface of secretory stage enamelof mammal.

34. The composition of paragraph 31, where the isolated aggregate isprepared from the outer layer enamel, newly formed enamel.

35. The composition of paragraph 31, where the isolated aggregate isseparated using a method selected from the group consisting of gelfiltration in alkaline solution, ion exchange chromatography, andammonium sulfate fractionation.

36. A method of producing an effect comprising administering the proteinof paragraph 31 to a mammal.

37. The method of paragraph 36, where the mammal is a Human.

38. A composition comprising isolated enamel proteins that comprise asheath protein.

39. The composition of paragraph 38, where the isolated enamel proteinsare prepared from the outer layer enamel, newly formed enamel,corresponding to approximately 30 μm thickness from the surface ofsecretory stage enamel of mammal.

40. The composition of paragraph 38, where the isolated enamel proteinsare extracted by an alkaline solution after the extraction of neutralsoluble proteins from the outer layer enamel, newly formed enamel.

41. A method of producing an effect comprising administering the proteinof paragraph 38 to a mammal.

42. The method of paragraph 41, where the mammal is a Human.

This invention is not limited to specific polypeptides or peptides andthe numerous modifications and variations therein will be apparent tothose skilled in the art. It is also to be understood that theterminology used herein is for the purpose of describing specificembodiments only and is not intended to be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings from part of the present specification and areincluded to further demonstrate certain aspects of the presentinvention. The invention may be better understood by reference to one ormore of these drawings in combination with the detailed description ofspecific embodiments presented herein.

FIG. 1 is a photograph of a surgical opening for the buccal dehiscencemodel in the beagle mandible. Bony defects are indicated by asterisks.

FIG. 2 is a light micrograph of the labial surface of porcine incisalsecretory enamel immunostained by using carboxyl-terminal specificanti-25 kDa amelogenin. The right half of surface enamel (arrowindicates the boundary) was scraped as an outer layer secretory enamel.

FIG. 3 is a protein profile of alkaline soluble fraction of newly formedenamel by Sephadex G-100 gel filtration and SDS-PAGE of obtainedfractions. A: alkaline soluble fraction of newly formed enamel, 1:fraction 1, 2: fraction 2, 3: fraction 3, 4: fraction 4. Fraction 1contained 13-17 kDa sheath proteins and 70-89 kDa enamelins and fraction2 contained mainly 20 kDa-25 kDa amelogenins. Fraction 3 and 4 containedamelogenin derivatives.

FIG. 4 is a light micrographs showing the cementum regenerated 8 weeksfollowing the application of EMDOGAIN® (A) and the fraction 1 (B) in theexperimental cavities created using the buccal dehiscence model. Key:upper part around the cervical margin (a), middle (b), bottom around thenotch created to enable the identification of the apical extension ofthe defect (c).

FIG. 5 is a graph showing the thickness of regenerated cementum byfraction 1, EMD and water (control). Statistically significantdifferences were recognized between each group (*: p<0.001).

FIG. 6 is a light micrographs showing the cementum regeneration eightweeks following application of EMD (a) and fraction 2 (b) on the buccaldehiscence type bone defects created along the premolars' roots ofcanine mandibles

FIG. 7-A: is a protein profile of fraction 1 further fractionated byDEAE ion exchange HPLC using EXPRESS-ION™ EXCHANGER Q column in 6M ureasolution (pH 7.4). The sheath proteins were eluted without retard alongwith a small amount of amelogenins. B: Protein profile of sheath proteinfraction further separated by gel filtration recycling system using aCellulofine GCL-2000 column in 4M guanidine solution (pH 7.4). Arrowsshow the connection position for recycling. Arrow head shows theposition connecting to fraction collector. SDS electrophoresis patternshows the separation between 17 kDa sheath protein and 15 kDa sheathprotein.

FIG. 8 is a light micrographs showing the cementum regeneration eightweeks following application of TGF-β1 (TGF-β), the 17 kDa sheath protein(17 kDa) and 15 kDa sheath protein (15 kDa) on the buccal dehiscencetype bone defects created along the premolars' roots of canine mandibles

FIG. 9 is the amino acid sequence of 17 kDa sheath protein (SEQ NO. 10)(A) and the relationship of the 17 kDa (SEQ NO. 10) and 15 kDa (sequencenot determined) sheath protein (B).

FIG. 10 is the protein profile of fraction 1 further fractionated by gelfiltration HPLC using double tandem TSKgelG3000PW columns. The proteinsin fraction 1 were separated using carbonate buffer (A). The firsteluted peak was then separated using guanidine buffer (B). Recyclingthrough this chromatography system purified the 17 (lane 1), 15 (lane 2)and 13 (lane 3) kDa sheath proteins to homogeneity (C).

FIG. 11 is the amino acid sequence of 17 kDa sheath protein (SEQ NO. 10)(A) and the relationship of the 17 kDa sheath protein (SEQ NO. 10) andits derivatives (B). The location of the synthetic peptides N-1 (SEQ IDNO: 18), N-2 (SEQ ID NO: 19), N-3 (SEQ ID NO: 20), C-1 (SEQ ID NO: 21),C-2 (SEQ ID NO: 22), and C-3 (SEQ ID NO: 23) are indicated. *1;N-terminal end of the 13 kDa sheath protein, *2; C-terminal end of the13 kDa and 15 kDa sheath protein. Arrows indicated cleavage sites.

FIG. 12 shows the ALP inducing activities of HPDL cells (A) and ST2Cells (B). Each purified sheath protein and synthetic peptide wasapplied at a final concentration of 50 μg/ml. The TGF-β1 and BMP-2 wereapplied 50 ng/ml and 500 ng/ml respectively. Data are means±SE of threeculture wells. Key: ag., aggregate; 17 kDa, 17 kDa sheath protein (SEQNO. 10); 15 kDa, 15 kDa sheath protein (sequence not determined); 13kDa, 13 kDa sheath protein (sequence not determined); sheath proteinsynthetic peptides N-1 (SEQ ID NO: 18), N-2 (SEQ ID NO: 19), N-3 (SEQ IDNO: 20), C-1 (SEQ ID NO: 21), C-2 (SEQ ID NO: 22), and C-3 (SEQ ID NO:23); bone morphogenetic protein-2, BMP-2; transforming growth factor-β1,TGF-β1.

FIG. 13 shows ALP inducing activities of HPDL cells of synthetic humanpeptides. H-1: SEQ ID NO: 3, H-2: SEQ ID NO: 1, H-3: SEQ ID NO: 2, H-4:SEQ ID NO: 4; and H-5: SEQ ID NO: 5.

FIG. 14 shows ALP inducing activities of HPDL cells of synthetic humanpeptides when adding TGF-β1 inhibitor (SB431542). 1: SEQ ID NO: 3, 2:SEQ ID NO: 1, 3: SEQ ID NO: 2, 4: SEQ ID NO: 4, 5: SEQ ID NO: 5, A: SEQID NO: 6, B: SEQ ID NO: 7, C: SEQ ID NO: 8. A, B and C were synthesizedbased on SEQ ID NO: 9, the N-terminal side sequence of porcine 6 kDaamelogenin

DESCRIPTION OF INVENTION Identification of Cementum Regeneration (CR)Promoting Factor in Porcine Enamel Proteins

Since no marker protein is found in the cementum formation, thehistological analysis on buccal dehiscence model of dogs are employedfor the identification of CR promoting factor, after application ofenamel proteins obtained at various purification steps. The CR promotingactivity is evaluated by the regenerated cementum determined byeight-week histological analysis on one-wall intrabony defects in beagledogs. After the determination of the protein having CR promotingactivity, the sequence shown bioactivity in the protein was searched bythe detection of ALP inducing activity of HPDL cells by application ofpurified enamel proteins or their peptides on cell culture system.Because, the ALP activity shows the cytodifferentiation of HPDL cellsand plays important function for acellular cementum formation. It isdeduced from morphometric evaluation in the light microscope onALP-deficient mice (Beertsen et al., 1999). The employment of cellculture system is handy method to link the detection ofcytodifferentiation activity in the enamel proteins. However, it isunclear at present whether the cytodifferentiation of HPDL cellsinvolves in cementogenesis or osteogenesis. Therefore, if CR promotingfactor was determined first, by the detection of cytodifferentiationactivity of HPDL cells is useful to determine bioactive sequence in theprotein shown CR promoting activity.

Regenerated Cementum Determined by Eight-Week Histological Analysis onOne-Wall Intrabony Defects in Beagle Dogs

Approximately 2-year-old male beagle dogs (approximate 15 kg) were usedto detect the CR activities after the applications of several enamelprotein samples. They had intact dentition and a healthy periodontium.The surgical preparation of buccal dehiscence type bone defects wascarried out according to the modified method of Hammarström (1997) undergeneral anesthesia induced and maintained by an endotracheal tube with1.5˜2.0% of halothane (Takeda Yakuhin Co. LTD, Osaka, Japan) in 100%oxygen, after premedicated with intramuscular injection of the mixtureof Ketamine HCl (9.8 mg/kg: Sankyo Co. LTD, Tokyo, Japan) and XylazineHCl (0.7 mg/kg: Bayer Co. LTD, Tokyo, Japan).

Contralateral buccal mucoperiosteal flaps were raised after anintracrevicular incision extending from the first mandibular premolar tothe first mandibular molar. After the removing the buccal alveolar boneplate covering the mesial root of the second premolars, the exposedperiodontal ligament and cementum of these areas were completely removedby means of a dental bur. At the apical end of the defect, a notch wascreated to identify the apical extension of the defect, whenhistological analyses. The distance between the cervical margin and theapical end of the defect was standardized at about 5 mm. The exposedroot dentin surfaces were conditioned for 2 min with cotton pelletssoaked in a 19% EDTA solution, and then carefully rinsed with sterilesaline. Then 50 μg of each enamel protein sample in 100 μl of coldsterile distilled water was applied over the entire buccal surface areaof the exposed roots. Finally, the mucoperiosteal flaps wererepositioned to their level prior to surgery and sutured. Distilledwater was used as a negative control and EMDOGAIN® (BIORA AB, Malmö,Sweden) served as a positive control.

After 8 weeks the dogs were terminated by anesthetization with sodiumpentobarbital. Their heads were fixed by perfusion with 0.1 M sodiumcacodylate buffer (pH 7.4) containing 4% paraformaldehyde and 1%glutaraldehyde. Tissue blocks, which included teeth, bone, and tissuewere dissected and demineralized in 10% formic acid containing 0.06 Msodium citrate and 0.1 M citric acid. All specimens were dehydratedusing a graded series of alcohols and then embedded in paraffin. Serialsections (5 μm thick) were made and stained with hematoxylin/eosin forexamination by light microscopy.

Evaluation of Regenerated Cementum Created on the Dentin Surface

The length and thickness of cementums regenerated after application offractionated and purified enamel protein samples and EMD were measuredon the computer monitor of histological results. The length of theregenerated cementum was straight distance between the apical end of thedefect and coronal extention of the new cementum, as well as to thecrest of the new alveolar bone. Also, the thickness of cementum wasmeasured at coronal end, apical end and between them. These data werestatistically analyzed by t-test.

When CR promoting factor is applied to the exposed root dentin surfaces,amelogenins which have no CR activity may be useful as the carrier of CRpromoting protein or peptide. Because the amelogenins aggregate eachother and precipitate at 37° Centigrade in ion strength of a living body(Shimizu and Fukae, 1983), although they are dissolved in distilledwater at low temperature. CR promoting protein or peptide comprise notonly CR promoting factor purified from mammalian immature enamel matrixbut also the synthesized peptide or recombinant protein or recombinantpeptide shown CR activity.

Preparation of Newly Formed Secretory Enamel

Unless stated otherwise, all steps were carried out at 4° C. or inice-cold conditions. Permanent incisor tooth germs are dissected fromthe fresh mandibles of six-month-old pigs which are purchased from theslaughter house and brought to lab in ice cold condition.

For the preparation of outer layer secretory enamel according to themethod of Fukae and Shimizu (1974), permanent incisor tooth germscontaining crown formation stage's developing tooth are selected. Afterthe removal of surrounding soft tissues including pulpa, tooth is rinsedin cold saline and wiped gently with Kimwipe paper (wipers S-200) toremove excess water. On the labial side of incisor, the secretory stageenamel which is soft like cheese and translucency, distinctly differentfrom the maturation stage's enamel of which the hardness is like chalkand collar is white. When the outermost layer beneath ameloblast celllayer of secretory enamel is prepared from the secretory stage enamel onlabial side of incisor tooth germs, thin razor blade is verticallytouched to the surface and moved gently and parallel to the surface. Thepeelings obtained by this behave corresponds approximately 30 μm depthfrom the surface of secretory enamel (Tanabe et al., 1992). Since theouter layer secretory enamel corresponds to the depth of approximately30 μm from the surface of secretory enamel beneath ameloblast celllayer, it is called to be newly formed secretory enamel. One morepeelings corresponded to approximately 30 μm˜60 μm depth is collected tobe outer-inner layer secretory enamel. This second layer was alsocollected since it contains the CR activity.

The inner layer sample was then scraped from the secretory enamel afterthe removal of a superficial layer of approximately 60 μm thickness.However, since this sample contained scarce cementum regenerationactivity, it was not used for the separation of the activity. Thecollected samples were stored in −80° C. These preparations are based onthe biochemical and histochemical evidences that the protein is mostabundant in the surface of secretory enamel and decreased from thesurface to enamel-dentin junction. The water, mineral and proteincontents of newly formed enamel are approximately 42%, 24% and 34% perwet weight respectively.

Enamel Protein Profiles and Identification of Enamel Proteins

Protein profiles of fractionated enamel proteins were examined byacrylamide gel electrophoreses using 15% polyacrylamide slab gelscontaining 1% sodium dodecyl sulfate (SDS) according of the method ofLaemmli (1970) and stained with Coomassie Brilliant Blue R-250. Theidentification of enamel proteins was carried out on Western blottinganalysis using polyclonal antibodies for amelogenin, enamelin and sheathproteins (Uchida et al., 1991). After electrophoresis the gel waselectro-transferred onto a GVHP membrane. The membrane was immunostainedusing the ABC kit and protocol (Vector Laboratories, USA), whichemployed the avidin-biotin complex method of Hsu et al., (1981).

Extraction of Porcine Enamel Proteins Containing CR Activity

Extraction of Neutral and Alkaline Soluble Fraction

The pooled samples were combined and added 20 times volume buffer perwet weight at ice cold condition. The protein in pooled sample wasextracted by homogenizing for a total of 60 seconds at approximately6,000 RPM using a Polytron homogenizer. To avoid heat up of the sampleduring homogenizing, 3 or 4 times interval were employed. The extractionusing the same buffer was repeated 3 times. The neutral soluble fractionand alkaline soluble fraction were sequentially extracted byhomogenizing in 0.05M Sörensen buffer (pH 7.4) and in 0.05Mcarbonate-bicarbonate buffer (pH 10.8) respectively (Fukae and Tanabe1987a). Over 95% of total protein was extracted by these sequentialextractions from the secretory enamel (Fukae and Tanabe, 1998).Approximately 16% of total proteins is solubilized in the neutral bufferand 80% is solubilized in the alkaline buffer.

When these neutral and alkaline soluble fractions separated from thenewly formed enamel are examined their CR activity using buccaldehiscence model of dogs, the CR activity is found only in the alkalinesoluble fraction. The residue after the alkaline buffer extraction iscrystals which are bound by the crystal bound proteins although theiramount is small. The crystal bound proteins are obtained bydemineralization using acidic condition such as 0.5M acetic acid or EDTAsolution. The composition of crystal bound proteins is quite similar tothe fraction 1 separated by Sephadex G-100 gel filtration from thealkaline soluble fraction of newly formed secretory enamel (Fukae andTanabe 1987a). Therefore it is expected that the crystal bound proteinshave the CR activity.

The extraction of neutral soluble fraction could be omitted since itsamount is not so big. However, neutral soluble fraction containsproenzyme of EMSP 1 (KLK4) and a small amount of active type of EMSP 1.Most of metalloproteinases are extracted in alkaline soluble fraction.To extract directly total soluble protein fraction using alkalinesoluble buffer by eliminating the step of neutral soluble fractionextraction causes that it contains proenzyme of EMSP 1 which is possiblyactivated by the action of metalloproteinases. It is possible that CRpromoting protein is degraded during its separation and purification.

Instead of homogenizing extraction, the extraction by gentle stirringcould be carried out overnight at cold room in neutral and alkalinesolution contained several kinds of proteinase and alkaline phosphataseinhibitors (5 mM benzamidine HCl, 2 mM 1,10-phenanthroline, 1 mMlevamisole) in cold room (Fukae et al., 1996).

Each whole protein of the outer layer, outer-inner layer and inner layerenamel sample could be solubilized by demineralizing using 0.5 M aceticacid or 0.5 M EDTA solution or by denatured solution such as 4 Mguanidine or 6-8 M urea in buffer. The methods using the denaturedsolution are disadvantage for the separation and purification of CRactivity containing fraction, because the extraction contained a lot ofdenatured reagent. It is the biggest problem that enamel proteinsconsist of a lot of amelogenins and their derivatives, which have theapproximate molecular weights and are characterized to have theaggregation nature.

Separation of CR Activity Containing Fraction

The alkaline soluble fraction of newly formed enamel sample was gelfiltrated into 4 fractions (fraction 1-4) using a column (2.6×100 cm) ofSephadex G-100 (Pharmacia Biotech, Uppsala, Sweden), which wasequilibrated with 0.05 M carbonate-bicarbonate buffer (pH 10.8). Theusage of carbonate buffer due to that the alkaline condition inhibitsthe aggregation of amelogenins. First eluted peak (fraction 1) containedmainly 70-89 kDa enamelins, 13-17 kDa sheath proteins and a small amountof 20-25 kDa amelogenins. Second peak (fraction 2), main peak contained20-25 kDa amelogenins. The others contained amelogenin derivatives.

The histological analysis of cementum regeneration eight weeks followingapplication of fraction 1 and EMD showed to evaluate the cementumregenerated on dentin surface. Both samples regenerated cementum fromthe notch to the cervical margin. The distance from the apical end ofthe bone defect to the new cementum was 6.24±0.40 mm, 6.15±0.43 mm and4.17±0.79 mm at fraction 1, EMD and control, respectively. There weresignificant differences between control and fraction 1 or EMD, but nosignificant difference between fraction 1 and EMD. Bone height from theapical end of the bone defect was 1.69±0.45 mm, 1.41±0.54 mm and1.09±0.46 mm at fraction 1, EMD and control, respectively. Significantdifference was found only between fraction 1 and control. The thicknessof cementum was measured at 3 points (apical, middle, coronal) of eachsample. The average thickness of cementum was 27.88±8.85 μm, 14.77±4.81μm and 8.37±2.48 μm at fraction 1, EMD and control, respectively.Statistical significant differences were recognized between each group.

The fraction 1 induced the formation of thick acellular cementum wellattached to the dentin. Numerous collagen fiber bundles arranged like innormal periodontium were produced from the regenerated cementum. The CRactivity (thickness of cementum) of EMD, which was the positive control,was obviously weaker than in fraction 1. The application of water usedas the negative control showed scarce CR activity.

The other fractions, which contained amelogenins and their derivatives,did not show the CR activity. This indicates that the amelogenins andtheir derivatives have no CR activity.

Except of Sephadex G-100 gel filtration, removal of abundant amelogeninscontained in newly formed enamel could be performed by ammonium sulfatefractionation (Kanazashi et al., 2004). Most amelogenins areprecipitated by approximately 6.5% saturation of ammonium sulfate in0.05M carbonate-bicarbonate buffer (pH 10.8) in ice cold condition. Thesupernatant was concentrated by ultrafiltration using YM-1 membrane touse next purification step. If the aggregate of sheath protein could befractionated by ammonium sulfate fractionation from immature secretoryenamel, the method is useful to prepare the practical remedy for CRpromoting since a large scale of sample is able to be prepared.

There is another method for removing abundant amelogenins from enamelproteins by the usage of their insolubility in neutral solution at hightemperature.

After enamel proteins are solubilized in acidic or alkaline solution atlower temperature, the solution is neutralized by adding alkaline oracidic solution and heated to 37° C. cause the precipitation ofamelogenins (Shimizu and Fukae 1983).

Separation of Aggregate Shown CR Activity

On Sephadex G-100 gel filtration of alkaline soluble fraction extractedfrom the outer layer sample, the first eluted peak (fraction 1)contained 70-89 kDa enamelins and the aggregate comprised of 13-17 kDasheath proteins along with a small amount of 20-25 kDa amelogenins. Ingeneral, the larger the protein, the earlier it elutes by gel filtrationchromatography. Therefore, the 13-17 kDa sheath proteins in fraction 1form the aggregate along with a small amount of 20-25 kDa amelogenins.Because when further fractionated using a double tandem TSKgel G-3000PWcolumn in carbonate buffer at room temperature, mostly the 13, 15, and17 kDa sheath proteins eluted first, 70-89 kDa enamelins next, andfinally the amelogenins. These small molecular weight sheath proteinslikely passed through the gel filtration column as an aggregate alongwith a small amount of amelogenins even in alkaline condition.

The bioactive fraction 1 from the Sephadex G-100 separation contained70-89 kDa enamelin and the aggregate of 13-17 kDa sheath proteins alongwith a small amount of 20-25 kDa amelogenins. If the fractions obtainedby this step were examined their CR activity by histological analyses,the aggregate consists of sheath proteins shows CR activity and enamelinfraction no CR activity.

The separation of aggregate from the fraction 1 could be also separatedby DEAE ion exchange HPLC column (9×100 mm) of EXPRESS-ION™ EXCHANGER Q(Whatman, Whatman International Ltd, Springfield Mill, England)equilibrated with 0.05M Tris-HCl buffer containing 6M urea (pH 7.4). Theproteins were eluted with a linear NaCl gradient (0-1.2 M). Theaggregate is not retarded in this column system, and pass through thecolumn, but the enamelin retarded and eluted in higher NaClconcentration. Therefore, the aggregate consisted of 13-17 kDa sheathproteins along with a small amount of 20-25 kDa amelogenins areseparated from 70-89 kDa enamelins around at neutral pH by DEAE ionexchange chromatography.

Purification of 13, 15 and 17 kDa Sheath Proteins

The fraction contained sheath proteins was further separated by gelfiltration recycle system using a column (2.5×95 cm) of CellulofineGCL-2000 (Chisso Ltd, Makuhari, Japan) or double tundem columns (7.5 mmI.D.×60 cm) of TSKgel G3000PW (TOSOH, Tokyo, Japan) equilibrated in0.05M Tris-HCl buffer contained 4M guanidine-HCl (pH7.4). The 13, 15 and17 kDa sheath proteins are purified by 12 times recycle system of TSKgelG3000PW column to be homogeneous.

The gel filtration by 12 times recycling of double tundem columns (7.5mm I.D.×60 cm) of TSKgel G3000PW is as same as the gel filtration usingover 28 m column of TSKgel G3000PW.

Amino Acid Sequence of 17 kDa Sheath Protein

Amino acid sequence analysis of each purified sheath proteins showedthat they are derived from sheathlin the parent protein (Hu et al.,1997a). Amino acid sequence analyses were carried out using SHIMAZDUprotein sequencer PPSQ-23A (Shimadzu Co., Kyoto, Japan).

Porcine 17 kDa sheath protein amino acid sequence is SEQ ID NO: 10.

The sequence of human sheath protein deduced from the human sheathlin(ameloblastin) sequence is SEQ ID NO: 11.

Characterization of Isolated 17, 15 and 13 kDa Sheath Proteins

Characterization of the isolated 17, 15, and 13 kDa sheath proteinsdemonstrate that the 17 and 15 kDa sheath proteins are N-terminalcleavage product of sheathlin containing 170 and 130 amino acids,respectively. The 13 kDa sheath protein contains the 99 amino acidsextending from M³² to Q¹³⁰.

Therefore, the 15 kDa sheath protein is produced by the cleavage ofC-terminal 40 amino acids of 17 kDa sheath protein. The 13 kDa sheathprotein is derived from the N-terminal side of 15 kDa sheath protein bysplitting out 31 amino acid residues.

Identification of CR Promoting Protein in Enamel Proteins

When purified 17 kDa and 15 kDa sheath protein were tested for thehistological analyses of cementum regeneration eight weeks (Kanazashi etal., 2006), the thickness of regenerated cementum after application of17 kDa and 15 kDa sheath protein was 31.77±3.78 μm and 8.13±2.06 μmrespectively. Therefore, the 17 kDa sheath protein induced a thickacellular cementum, but the 15 kDa sheath protein showed scarce CRactivity.

The evidence shows that 17 kDa sheath protein is the CR promotingprotein and the CR activity resides in the C-terminal side peptide of 17kDa sheath protein, of which the peptide is not in the 15 kDa sheathprotein. Porcine bioactive sequence shown CR promoting activity is SEQID NO: 12. Deduced human bioactive sequence is SEQ ID NO: 13.

And so, to determine the shortest bioactive sequence is examined by thedetection of ALP inducing activity of HPDL cells.

Identification of Sequence Having Cytodifferentiation Activity by theDetection of ALP Inducing Activity of HPDL Cells on Cell Culture System

Cell Culture of HPDL Cells and Alp Activity Assay

Human periodontal ligament (HPDL) cells were obtained according to themethod of Somerman et al., (1988) from healthy premolars which wereextracted from the patients for orthodontic reasons. The cells wereprecultured for 4-6 passages with a-MEM medium to establish the primarycell line. The cells were maintained in the alpha modification ofEagle's medium (α-MEM; Life Technologies, Grand Island, N.Y., USA)containing 10% fetal bovine serum (FBS; Asahi Technoglass, Chiba, Japan)and 1% antibiotics (100 U/ml of Penicillin-G and 100 μg/ml ofStreptomycin sulfate; Gibco BRL, Grand Island, N.Y., USA) at 37° C. in ahumidified 5% CO₂ atmosphere. The ST2 cells (Riken Cell Bank, Tsukuba,Japan), an osteoblast-like mouse bone marrow stromal cell line, werecultured under the same conditions.

HPDL cells were distributed in 96-well plates at a density ofapproximately 5×10⁵ cells per a well and incubated for 24 h. The growthmedium was then changed to contain 10 nM of 1α-25-dihydroxy-Vitamin D₃(CALBIOCHEM, La Jolla, Calif.) and 50 μg/ml (final concentration) offractionated enamel protein samples or synthesized peptides dissolved inultrapure water. After 96 additional hours of incubation, the cells werewashed once with PBS, and ALP activity was determined after a 10 minincubation at 37° C. in 10 mM p-nitrophenylphosphate (substrate) in 100mM 2-amino-2-methyl-1,3-propanediol-HCl buffer (pH 10.0) containing 5 mMMgCl₂. After adding 0.2 M NaOH, which stopped the reaction, theabsorbance at 405 nm was read on a plate reader. Controls included theuse of recombinant growth factors (BMP-2 500 ng/ml; TECHNE Co.,Minneapolis, USA, TGF-β1 50 ng/ml; R&D Systems, Inc., Minneapolis, USA).

In cell culture systems of the HPDL cells and ST2 cells, the 1α-25-dihydroxy-Vitamin D₃ plays the important role for the induction ofALP activity of HPDL and ST2 cells. The ALP activity of HPDL cellsincreased by stimulation of 1 α-25-dihydroxy-Vitamin D₃ is furtherincreased by stimulation of TGF-β1, but reduced by stimulation of BMP-2.It is shown that the HPDL cells stimulated by TGF-β1 induce themineralization in long term cell culture (Nagano, 2003). In contrast,the ALP activity of ST2 cells is increased by stimulation of BMP-2, butis not stimulated by TGF-β1. If the ALP activity of HPDL cells werestimulated by BMP-2, it is shown that the cytodifferentiation of thecells direct to osteoblast-like cells.

Mineralization Activity

The HPDL cells were plated in 24-well plates at an initial density of1×10⁵ cells/well. After 24 h of incubation, the medium was replaced withgrowth medium containing 50 μM ascorbic acid, 10 mM β-glycerophosphate,and 10 nM 1α,25-dihydroxyvitamin D₃ (differentiation medium) and 1 μg/mlof samples. The medium was changed every 72 h. The cells were maintainedfor 30 days and then the medium was discarded.

The compartments of cells were fixed in 100% methanol, stained withalizarin red S for 10 min, then washed with ultrapure water andphotographed to examine the biomineralization activity. The stainingsolution was 1% alizarin red S (sodium alizarin sulfonate) (Sigma)dissolved in ultrapure water and adjusted to pH 6.4 with 0.1N ammoniumhydroxide.

For measuring the calcium content, the compartments of cells weredissolved by 0.5N hydrochloric acid. The resulting solution was measuredby a Calcium C-test kit and protocol (Wako Pure Chemical Industries Ltd,Osaka, Japan). The absorbance at 570 nm was read on a plate reader.

ALP Inducing Activity of Purified Sheath Proteins or Synthetic PeptidesUsing Cell Culture of HPDL and ST2 cells

HPDL cells of approximately 5×10⁵ cells per well were distributed in96-well plates and incubated for 24 h. The growth medium was thenchanged to contain 10 nM of 1α-25-dihydroxy-Vitamin D₃ and 50 μg/ml(final concentration) of purified sheath protein or synthesized peptide.After 96 additional hours of incubation, ALP activity was determinedusing p-nitrophenylphosphate as a substrate. For positive controls, therecombinant BMP-2 and TGF-β1 were added 500 ng/ml and 50 ng/ml,respectively.

Each purified sheath proteins were examined to increase the ALP activityof HPDL and ST2 cells on cell culture system. The ALP activity of theHPDL cells was enhanced by the addition of the 17 kDa sheath protein,but not by the 15 or 13 kDa sheath proteins. The sheath proteins did notenhance the ALP activity of ST2 cells, which were enhanced by adding theBMP-2. These evidences indicate that the cytodifferentiation activityresides in C-terminal side peptide of 17 kDa sheath protein, which isnot contained in the 15 kDa sheath protein, since 15 kDa sheath proteinsis derived from the 17 kDa sheath protein by splitting out theC-terminal side peptides. It is suggested that the cytodifferentiationactivity shown by the cell culture system links strongly to CR promotingactivity determined in in vitro system of buccal dehiscence model ofdogs.

In some case, the application of 15 kDa sheath protein in HPDL cellculture system showed the increase of ALP inducing activity than that of13 kDa sheath protein. It indicates N-terminal side peptide of 17 kDasheath protein may have also the cytodifferentiation activity of HPDLcells, although its activity is small.

When 25 kDa amelogenin and amelogenin derivatives (6 kDa, 13 kDa, 20kDa) purified from porcine immature enamel matrix were examined theirALP inducing activity of HPDL cells on the cell culture system, theyhave the activity like TGF-β1. The 20 kDa amelogenin is derived bysplitting out C-terminal hydrophilic peptide from 25 kDa amelogenin,most abundant uncleaved amelogenin polypeptides in the porcine geneproducts. This degradation occurs in the outer layer secretory enamel bythe action of MMP-20. The 20 kDa amelogenin is degraded into two pieces,6 kDa and 13 kDa amelogenins by the action of EMSP1 during the advanceddevelopmental secretory enamel. The 6 kDa amelogenin derived fromN-terminal side and 13 kDa amelogenin is derived from C-terminal side of20 kDa amelogenin. In these amelogenin and its derivatives, 6 kDaamelogenin have the strongest ALP inducing activity of HPDL cells.Moreover, N-terminal side peptide of 6 kDa amelogenin, SEQ ID NO: 6 hadALP inducing activity in synthesized peptides deduced from sequence of 6kDa amelogenin. These indicate that amelogenin have cytodifferentiationactivity of HPDL cells as same as the sheath protein. However, sinceamelogenins have no CR promoting activity on buccal dehiscence model ofdogs, they may involve in the induction of osteogenesis duringperiodontal regeneration.

Amino acid sequence of porcine 6 kDa amelogenin is SEQ ID NO: 14.

Synthetic Peptides

A-1: SEQ ID NO: 15

A-2: SEQ ID NO: 16

A-3: SEQ ID NO: 17

A-1-1: SEQ ID NO: 6

A-1-2: SEQ ID NO: 7

A-1-3: SEQ ID NO: 8

The peptides synthesized based on the amino acid sequence of 6 kDaamelogenin were examined their ALP inducing activity of HPDL cells incell culture system. Since N-terminal side peptide (A-1) showed thestrong bioactivity, more shorter peptides were synthesized based on thesequence of A-1 and examined their bioactivity. The result shows thatA-1-1 and A-1-2 promote ALP inducing activity of HPDL cells in cellculture system. The A-1-1 peptide promotes the bioactivity at highconcentration (1 μg/ml) and the A-1-2 peptide at low concentration (10ng/ml) in cell culture system.

It is unclear at present whether the cytodifferentiation activity ofHPDL cells revealed by the increase of ALP inducing activity in cellculture system induces cementogenesis or osteogenesis. It is wellaccepted that osteoblasts express RANKL (ODF) to produce osteoclastsinvolved in bone resorption after the stimulation of1α-25-dihydroxy-Vitamin D₃. On the other hand, cementoblasts is notinvolved in cement resorption. And so, the expression of RANKL detectedby using its specific antibody or its mRNA detected by RT-PCR could beuseful to determine whether cytodifferentiation of HPDL cells indicatedcementogenesis or osteogenesis.

Synthesized Peptides

Six peptides are synthesized as followed based on the N- and C-terminalside sequence of porcine 17 kDa sheath protein.

Their sequences are SEQ ID NO: 18 (N-1), SEQ ID NO: 19 (N-2), SEQ ID NO:20 (N-3), SEQ ID NO: 21 (C-1), SEQ ID NO: 22 (C-2) and SEQ ID NO: 23(C-3) respectively.

The bioactivities of the synthetic peptides were also tested using thecell culture system of HPDL and ST2 cells. When application of 50 μg/mlof the C-1 peptide, which is at the C-terminus of the 17 kDa sheathprotein and not found on either the 15 or 13 kDa sheath proteins, itenhanced the ALP activity of the HPDL cells. Some of the other peptidesreduced the ALP activity of HPDL cells, as did BMP-2. However, nosynthesized peptide enhanced the ALP activity of ST2 cells.

In this experiment, a fault is that approximately 10 times highconcentration of synthetic peptide compared with 17 kDa sheath proteinwas applied to detect the increase of ALP inducing activity of HPDLcells. The average molecular weight of synthetic peptides isapproximately 1.6 kDa and the molecular weight of 17 kDa sheath proteinis approximately 18 kDa, deduced from its amino acid composition.

It is suspected that the bioactivity of C-1 peptide induced thecytodifferentiation of HPDL cells by the application of highconcentration (50 μg/ml) is not so strong.

In some case, the application of peptide synthesized based on theN-terminal side sequence of 17 kDa sheath protein in HPDL cell culturesystem showed the increase of ALP inducing activity, although theiractivity were small. It indicates N-terminal side peptide of 17 kDasheath protein may have the cytodifferentiation activity of HPDL cells,which link to CR activity.

Human Synthetic Peptides Based on the C-Terminal Side of Human SheathProtein

The human extra C-terminal side peptide contains 66 amino acid residuesdifferent from the 40 residues of porcine extra C-terminal peptide. Andso, 5 peptides were synthesized based on the sequence of 66 amino acids.

Their sequences are SEQ ID NO: 3 (H-1), SEQ ID NO: 1 (H-2), SEQ ID NO: 2(H-3), SEQ ID NO: 4 (H-4) and SEQ ID NO: 5 (H-5).

The bioactivities of the synthetic peptides were tested using the cellculture system of HPDL and ST2 cells. When application of around 1 ng/mlof the H-2 and H-3 peptides, they enhanced dose dependently the ALPactivity of the HPDL cells. The other peptides also enhanced the ALPactivity of HPDL cells, although their activities are weaker than H-2 orH-3. No synthesized peptide enhanced the ALP activity of ST2 cells.

In the case of TGF-β1, around 10 ng/ml of TGF-β1 is apt concentrationfor increasing ALP inducing activity of HPDL cells in cell culturesystem. Since average molecular weight of synthetic peptides is 1.5 kDa,adapted concentration of these peptides for increasing ALP inducingactivity of HPDL cells is 0.6 nM/liter. Since the molecular weight ofTGF-β1 is 25 kDa, its concentration is 0.4 nM/liter. The activity ofthese peptides is almost similar concentration level as that of TGF-β1,growth factor.

When TGF-β1 receptor inhibitor (SB431542) was applied into HPDL cellculture system, the ALP inducing activity of TGF-β1 was inhibiteddistinctly. However, ALP inducing activity increased by application ofsynthetic peptide was not inhibited by adding SB431542. It is suggestedcytodifferentiation activity of synthetic peptides is induced via theother receptor different from TGF-β1 receptor.

The usage of synthetic peptides is due to avoid a risk of infection of Etype or unknown virus, and immunity for repeat application of CRpromoting protein to the same patient. Bioactive synthetic peptidehaving CR activity should be effective to apply for treatment ofperiodontal disease. The synthetic peptide deduced from human sheathprotein sequence is available to treat the periodontal disease of Islampatients

The outer, outer-inner and inner layer secretory enamel were preparedfrom the labial side of permanent incisor tooth of crown formation stageobtained from approximately 20 porcine mandibles. Each average wetweight of sample obtained one time is shown as below. Each sample wassequentially prepared from immature enamel of incisor tooth withavoiding the contamination of each other. Therefore, the sample loss atthe preparation should be taken into consideration.

Wet weight protein content Outer enamel sample 0.064 g 0.022 g (0.044g-0.085 g) Outer-Inner enamel 0.153 g 0.041 g sample (0.145 g-0.159 g)Inner enamel sample 2.290 g 0.498 g (2.209 g-2.449 g) Total secretorystage 2.507 g 0.561 g enamelWet weight of O+O−I/Total wet weight of secretory stage enamel=8.65%(7.0%-10.2%)Protein content of each sample was calculated from the values in Table1.Protein of O+O—I/Total protein of secretory stage enamel=11.2%(9.1%-13.2%)

Proteins of O+O—I means since not only outer layer but also outer-innerlayer sample contain 17 kDa sheath protein.

Fraction 1 separated by Sephadex G-100 contained the aggregate of sheathproteins was approximately 14.4% in outer plus outer-inner layer sample,which was used as previous preparation (Fukae and Tanabe, 1987).

Therefore, protein fraction contained the aggregate of sheath proteins,which corresponded to contain fraction 1 separated by Sephadex G-100 andcrystal bound proteins (negligible small), is 11.2×0.151=1.69%(1.37%-1.99%) of total protein in secretory stage enamel.

On practical extraction experiment, 45 mg of fraction 1 was obtainedfrom 2 g of the outer layer sample. Ninety nine mg of fraction 1 shouldbe obtained theoretically from the sample by calculation. In this casethe content of fraction 1 was calculated to be 0.26% (0.57%theoretically) of total protein in secretory enamel withoutconsideration of fraction contained in outer-inner layer secretoryenamel.

The aggregate fraction was obtained 12.7 mg from 45 mg of fraction 1.Therefore, the content of aggregate fraction was 0.07% (0.17%theoretically) of total protein of secretory enamel.

The content of 17 kDa sheath protein was calculated to be approximately0.023%, (0.056% theoretically) of total protein of secretory enamel.Because 17 kDa sheath protein is contained approximately 33% fromdensitometric analysis on SDS acrylamide gel electrophoretic pattern ofthe aggregate obtained by gel filtration or ion exchange chromatography.The value was calculated on hypothesis that all proteins had the samestainabilty by CBB staining.

At Present Fraction 1 Shows the Best CR Promoting Activity on Eight-WeekHistological Analysis on One-Wall Intrabony Defects in Beagle Dogs.

When fraction 1 separated by Sephadex G-100 gel filtration from thealkaline soluble extract of the porcine outer layer secretory enamel wasapplied to a periodontal defect in the buccal dehiscence model, completeregeneration was induced on the dentin surface. Fraction 1 induced theformation of a thick acellular cementum well-attached to dentin from thenotch to the cervical margin. Abundant collagen fiber bundles, arrangedlike in a normal periodontium, were produced from the regeneratedcementum. These results are based on the facts that the length andthickness of cementums regenerated were measured on the computer monitorof histological results and statistically analyzed by t-test.

The stronger CR activity of fraction 1 compared with EMDOGAIN® is due tothe concentration of an active ingredient of EMDOGAIN®. A considerableamount of amelogenin was removed during the preparation of fraction 1and the concentration of the 17 kDa sheath protein, which was the truebioactive component in this fraction, increased. However, the 17 kDasheath protein induced thick acellular cementum near the apical end ofthe defect, but the CR was scarce near the coronal end. Epithelialdowngrowth was observed sometimes. These were different from theresults-of the fraction 1 application. The absence of amelogenin maycause the decrease of the scope of the cementum regeneration, and ittherefore might support as a carrier the CR activity of the 17 kDasheath protein.

To solve EMD propylene glycol alginate is used as a carrier at practicalclinical application. When CR promoting protein or peptide is applied tothe exposed root dentin surfaces, amelogenins, which havecytodifferentiation activity but no CR activity, may be useful for thecarrier of it. Because the amelogenins dissolved in cold distilled wateraggregate each other to precipitate at 37° C. in ion strength of aliving body (Shimizu and Fukae, 1983) and attach to the exposed dentinsurface.

Recombinant sheath protein or bioactive peptide showing CR activitycould be made based on human sheathlin (ameloblastin) cDNA preparedusing human odontoblasts (Nagano et al., 2003). Human odontoblasts wereobtained according to the method of Oida et al., (2002) from healthypremolars which were extracted from the patients for orthodonticreasons. Fresh extracted tooth was cut down longitudinally with bonechisel and after the pulp was removed with tweezers odontoblastsremained on the predentin surface were peeled. Since the expression ofamelogenin, enamelin, sheathlin, MMP-20 and KLK4 are detected inodontoblasts, total RNA was extracted with the Stratagene Total RNAMiniprep Kit and protpcol (Stratagene, La Jolla, Calif., USA).

TABLE 1 Chemical composition of outer, outer-inner, inner layersecretory enamel (wet weight %) total neutral alkaline water mineralprotein sol. frac. sol. frac. Outer 42 24 34 5.4 29 (0-30 μm)outer-inner 35 38 27 5.1 21 (30-60 μm) Inner 34 47 19 5.1 13 (60-300 μm)

TABLE 2 Protein yields in the neutral, alkaline and acid solublefractions of outer, outer-inner and inner layer secretory enamel (dryweight %) Neutral sol. Alkaline sol. Acid sol. Total protein fractionfraction fraction outer 59.3 9.5 (16) 47 (80) 3.6 (4) outer-inner 40.87.8 (19) 31 (77) 4.0 (4) inner 28.8 7.8 (27) 20 (68) 4.5 (5)

Porcine 17 kDa sheath protein amino acid sequence SEQ ID NO: 10 SequenceSize 170 Sequence Position 1-170 hydrophobic 94 (55.29) neutral 46(27.06) hydrophilic 30 (17.65) other  0 (0.00) [hydrophobic residues]Gly(G) 12 (7.06%) Ala(A) 6 (3.53%) Val(V) 10 (5.88%) Leu(L) 16 (9.41%)Ile(I) 3 (1.76%) Met(M) 6 (3.53%) Phe(F) 8 (4.71%) Trp(W) 2 (1.18%)Pro(P) 31 (18.24%) [neutral residues] Ser(S) 15 (8.82%) Thr(T) 5 (2.94%)Asn(N) 3 (1.76%) Gln(Q) 23 (13.53%) Cys(C) 0 (0.00%) [hydrophilicresidues] Asp(D) 3 (1.76%) Glu(E) 8 (4.71%) Lys(K) 4 (2.35%) His(H) 5(2.94%) Arg(R) 6 (3.53%) Tyr(Y) 4 (2.35%) [other residues] Asx(B) 0(0.00%) Glx(Z) 0 (0.00%) Xaa(X) 0 (0.00%) Average Molecular Weight =18885.15 Monoisotopic Molecular Weight = 18873.5067

The sequence of human sheath protein deduced from the human sheathlin(ameloblastin) sequence SEQ ID NO: 11. Sequence Size 196 SequencePosition 1-196 hydrophobic 109 (55.61) neutral  50 (25.51) hydrophilic 37 (18.88) other  0 (0.00) [hydrophobic residues] Gly(G) 15 (7.65%)Ala(A) 11 (5.61%) Val(V) 5 (2.55%) Leu(L) 26 (13.27%) Ile(I) 3 (1.53%)Met(M) 5 (2.55%) Phe(F) 9 (4.59%) Trp(W) 2 (1.02%) Pro(P) 33 (16.84%)[neutral residues] Ser(S) 18 (9.18%) Thr(T) 8 (4.08%) Asn(N) 3 (1.53%)Gln(Q) 21 (10.71%) Cys(C) 0 (0.00%) [hydrophilic residues] Asp(D) 7(3.57%) Glu(E) 8 (4.08%) Lys(K) 6 (3.06%) His(H) 6 (3.06%) Arg(R) 6(3.06%) Tyr(Y) 4 (2.04%) [other residues] Asx(B) 0 (0.00%) Glx(Z) 0(0.00%) Xaa(X) 0 (0.00%) Average Molecular Weight = 21419.96Monoisotopic Molecular Weight = 21406.8663

Porcine bioactive sequence shown CR promoting activity SEQ ID NO: 12Sequence Size 40 Sequence Position 1-40 hydrophobic 24 (60.00) neutral 7 (17.50) hydrophilic  9 (22.50) other  0 (0.00) Average MolecularWeight = 4347.81 Monoisotopic Molecular Weight = 4345.1035

Human bioactive sequence shown CR promoting activity SEQ ID NO: 13.Sequence Size 66 Sequence Position 1-66 hydrophobic 41 (62.12) neutral12 (18.18) hydrophilic 13 (19.70) other  0 (0.00) Average MolecularWeight = 6935.60 Monoisotopic Molecular Weight = 6931.4326

Possible CR promoting activity sequence of N-terminal side of porcine 17kDa sheath protein SEQ ID NO: 24. Sequence Size 31 Sequence Position1-31 hydrophobic 19 (61.29) neutral  9 (29.03) hydrophilic  3 (9.68)other  0 (0.00) Average Molecular Weight = 3222.67 MonoisotopicMolecular Weight = 3220.7022

Possible CR promoting activity sequence of N-terminal side of Humansheath protein SEQ ID NO: 25. Sequence Size 31 Sequence Position 1-31hydrophobic 17 (54.84) neutral 11 (35.48) hydrophilic  3 (9.68) other  0(0.00) Average Molecular Weight = 3391.88 Monoisotopic Molecular Weight= 3389.7220

Six peptides are synthesized as followed based on the N- and C-terminalside sequence of porcine 17 kDa sheath protein. N-1: SEQ ID NO: 18, N-2:SEQ ID NO: 19, N-3: SEQ ID NO: 20, C-1: SEQ ID NO: 21, C-2: SEQ ID NO:22, and C-3: SEQ ID NO: 23 N-1: SEQ ID NO: 18 Sequence Size 13 SequencePosition 1-13 hydrophobic 10 (76.92) neutral  2 (15.38) hydrophilic  1(7.69) other  0 (0.00) Average Molecular Weight = 1322.49 MonoisotopicMolecular Weight = 1321.7143 N-2: SEQ ID NO: 19 Sequence Size 13Sequence Position 1-13 hydrophobic  7 (53.85) neutral  4 (30.77)hydrophilic  2 (15.38) other  0 (0.00) Average Molecular Weight =1361.57 Monoisotopic Molecular Weight = 1360.7019 N-3: Sequence No. 20Sequence Size 13 Sequence Position 1-13 hydrophobic 6 (46.15) neutral 5(38.46) hydrophilic 2 (15.38) other 0 (0.00) Average Molecular Weight =1446.64 Monoisotopic Molecular Weight = 1445.7294 C-1: SEQ ID NO: 21Sequence Size 170 Sequence Position 132-146 Average Molecular Weight =1626.82 Monoisotopic Molecular Weight = 1625.8084 C-2: SEQ ID NO: 22Sequence Size 170 Sequence Position 144-158 Average Molecular Weight =1599.72 Monoisotopic Molecular Weight = 1598.7827 C-3: SEQ ID NO: 23Sequence Size 170 Sequence Position 156-170 Average Molecular Weight =1706.88 Monoisotopic Molecular Weight = 1705.7770 Peptides synthesizedbased on the sequence of human extra C-terminal side peptide (66 aminoacids). H-1: SEQ ID NO: 3, H-2: SEQ ID NO: 1, H-3: SEQ ID NO: 2, H-4:SEQ ID NO: 4, and H-5: SEQ ID NO: 5 H-1: SEQ ID NO: 3 Sequence Size 196Sequence Position 131-144 Average Molecular Weight = 1494.64Monoisotopic Molecular Weight = 1493.7725 H-2: SEQ ID NO: 1 SequenceSize 196 Sequence Position 144-157 Average Molecular Weight = 1525.68Monoisotopic Molecular Weight = 1524.7824 H-3: SEQ ID NO: 2 SequenceSize 196 Sequence Position 157-170 Average Molecular Weight = 1478.62Monoisotopic Molecular Weight = 1477.6546 H-4: SEQ ID NO: 4 SequenceSize 196 Sequence Position 170-183 Average Molecular Weight = 1486.61Monoisotopic Molecular Weight = 1485.7138 H-5: SEQ ID NO: 5 SequenceSize 196 Sequence Position 183-196 Average Molecular Weight = 1550.72Monoisotopic Molecular Weight = 1549.7889

Example 1 Material & Methods

All experimental procedures involving the use of animals had beenreviewed and approved by the Institutional Animal Care Program ofTsurumi University.

Detection of CR Promoting Activity

CR promoting activity of enamel proteins obtained at each extracted andpurified step were examined by eight-week histological analysis ofbuccal dehiscence type bone defects created along the roots of caninemandible (FIG. 1).

Extraction of Enamel Proteins

From porcine secretory enamel, the outer layer sample (newly formedenamel) and inner layer sample were prepared. From these samples,neutral soluble and alkaline soluble fractions were extractedsequentially by homogenizing in the buffer for short term. CR promotingactivity was found in alkaline soluble fraction of outer layer secretoryenamel. And then the CR promoting protein was separated by SephadexG-100 gel filtration, DEAE ion exchange chromatography and finerypartially purified by a gel filtration recycle system using a column ofCellulofine GCL-2000 in 4M guanidine solution.

Results

The thickness of outer layer enamel was approximately 30 μm from thesurface of secretory enamel (FIG. 2). Water, mineral and proteincontents of outer layer secretory enamel were 42%, 24% and 34%,respectively (Table 1). Protein distribution of neutral and alkalinesoluble fraction extracted from the outer layer enamel was 16% and 80%of total protein, respectively (Table2).

TABLE 1 Alkaline Total Neutral soluble soluble Water Mineral proteinfraction fraction Outer 42 24 34 5.4 29 (0-30 μm) Outer-inner 35 38 275.1 21 (30-60 μm) Inner 34 47 19 5.1 13 (60-300 μm)

TABLE 2 Protein yields in the neutral, alkaline and acid solublefractions of each enamel sample (Dry weight %) Total Neutral solubleAlkaline soluble Acid soluble Sample proteins fraction fraction fractionOuter 59.3 9.5 (16) 47 (80) 3.6 (4) Outer-inner 40.8 7.8 (19) 31 (77)4.0 (4) Inner 28.8 7.8 (27) 20 (68) 4.5 (5) Parentheses show the proteincontent per total proteins

CR activity was found in the outer layer (newly formed) enamel samplerather than in the inner layer enamel sample on histological analysis onbuccal dehiscence model of dogs. In the newly formed enamel sample, theCR activity was found in the alkaline soluble fraction, but not in theneutral soluble fraction.

The alkaline soluble fraction of newly formed enamel was separated intofour fractions by Sephadex G-100 gel filtration (FIG. 3). The CRactivity in these fractions was found in the first eluted peak (fraction1), but not in the other fractions contained only amelogenins and theirderivatives.

The histological analysis of cementum regeneration eight weeks followingapplication of fraction 1 and EMD showed both samples regeneratedcementum from the notch to the cervical margin (FIG. 4). The thicknessof cementum was measured at 3 points (apical, middle, coronal) of eachsample. The average thickness of cementum was 27.88±8.85 μm, 14.77±4.81μm and 8.37±2.48 μm at fraction 1, EMD and control (ddH₂O),respectively. Statistical significant differences were recognizedbetween each group (FIG. 5). The fraction 1 induced the formation ofthick acellular cementum well attached to the dentin. Numerous collagenfiber bundles arranged like in normal periodontium were produced fromthe regenerated cementum (FIG. 4-B). The CR activity (thickness ofcementum) of EMD, which was the positive control, was obviously weakerthan in fraction 1 (FIG. 4-A). The application of water used as thenegative control showed scarce CR activity.

The fractions, except fraction 1, separated by Sephadex G-100 gelfiltration containing amelogenins or their derivatives (fraction 2) didnot show CR activity (FIG. 6-b).

It was shown on SDS electrophoreses that fraction 1 containing 70 kDa˜89kDa enamelin and 13˜17 kDa sheath proteins along with a small amount of20˜25 kDa amelogenins. These sheath proteins formed the aggregate sincethe lower molecular weight sheath proteins were eluted at an elutionposition of high molecular weight protein.

The aggregate fraction was separated from the fraction 1 by ion exchangechromatography (FIG. 7-A) and examined for its CR activity. There was CRactivity in the sheath protein fraction, but not in the enameling.

Partially purified 17 kDa and 15 kDa sheath proteins by gel filtrationrecycle system using a column of Cellulofine GCL-2000 (FIG. 7-B) weretested for their CR activity (FIG. 8). Further purified 17 kDa sheathprotein induced a smaller area of cementum regeneration on the dentinsurface of experimental cavities created on premolar medial roots,although the regenerated cementum was thick. The thickness of cementumwas 31.77±3.78 μm and 8.13±2.06 μm with 17 kDa and 15 kDa, respectively.The 15 kDa sheath protein showed scarce CR activity. The amino acidsequence analyses of purified sheath proteins demonstrated that the 17and 15 kDa sheath proteins corresponded to the N-terminal side ofsheathlin containing 170 and 130 amino acids, respectively (FIG. 9).These indicated that the CR activity found in the 17 kDa sheath proteinwas located in its C-terminal side peptide, which was not found in the15 kDa sheath protein.

Discussion

Compared with the application of EMD which showed obvious CR activity asreported previously, stronger CR activity was found reproducibly in thefraction 1 separated by Sephadex G-100 gel filtration from the alkalinesoluble fraction of newly formed secretory enamel. The fraction 1consisted of enamelins and sheath proteins formed an aggregate alongwith a small amount of amelogenins. It was determined from histologicalanalysis that the 17 kDa sheath protein exhibited the CR activity, andthe amelogenins and enamelins showed no CR activity.

However, further purified 17 kDa sheath protein induced a smaller areaof cementum regeneration, although the regenerated cementum was thick.The result may be because water was employed for dissolution of thesample, different from the employment of propylene glycol alginate forEMD (Hammarström et al., 1997). Moreover, it is possible that this wasdue to the lack of amelogenins, because amelogenin may act as a carrierof CR promoting factor.

When partially purified 17 kDa and 15 kDa sheath proteins were testedfor their CR activity, the 17 kDa sheath protein showed CR promotingactivity, but the 15 kDa sheath protein showed scarce CR activity. Basedon their amino acid sequence the 15 kDa sheath protein was derived bysplitting out C-terminal side peptide from 17 kDa sheath protein. Theseindicated that the CR activity found in the 17 kDa sheath protein waslocated in its C-terminal side peptide, which was not found in the 15kDa sheath protein. CR promoting peptide is SEQ ID NO: 12.

Example 2 Material & Methods

For the usage of human cells, informed consent was obtained from allpatients under a protocol (No. 103) approved by the Ethics Committee atTsurumi University.

Purification of Sheath Proteins

Since CR promoting activity was determined in sheath proteins whichresided in newly formed secretory enamel, they were purified to behomogeneous. The aggregate of sheath proteins was separated by SephadexG-100 Superfine gel filtration from the alkaline-soluble fraction of theouter enamel layer sample. It was further separated by HPLC using doubletandem TSKgel G-3000PW columns (TOSOH, Tokyo, Japan; 7.5 mm I.D.×60 cm)in the carbonate buffer (pH 10.8). The sheath proteins in the aggregateof the first eluted peak were purified to homogeneity by recycle overthe double tandem TSKgel G-3000PW columns equilibrated with 4 Mguanidine solution (pH 7.4) buffer.

Six peptides were synthesized based on the amino acid sequences of N-and C-terminal side of 17 kDa sheath protein

These purified sheath proteins and the peptides synthesized based on thesequence of 17 kDa sheath protein were examined theircytodifferentiation activity of HPDL cells by determination ofincreasing ALP inducing activity on cell culture system.

Results

Purification and Characterization of the Sheath Proteins

The sheath proteins were purified by gel filtration recycling systemusing double tandem TSKgel G-3000PW columns in guanidine buffer (FIG.10). Characterization of the isolated 17, 15, and 13-kDa sheath proteinsdemonstrate that the 17 and 15-kDa sheath proteins are N-terminalcleavage product of sheathlin, containing 170 and 130 amino acids,respectively. The 13-kDa sheath protein contains the 99 amino acidsextending from M³² to Q¹³⁰ (FIG. 11).

Based on N- and C-terminal side sequence of 17 kDa sheath protein sixpeptides were synthesized and their ALP inducing activity of HPDL cells.Their sequences are SEQ ID NO: 18 (N-1), SEQ ID NO: 19 (N-2), SEQ ID NO:20 (N-3), SEQ ID NO: 21 (C-1), SEQ ID NO: 22 (C-2) and SEQ ID NO: 23(C-3) respectively.

Sheath proteins purified from the aggregate were examined for the ALPinducing activity of HPDL and ST2 cells in culture. The ALP activity ofthe HPDL cells was enhanced by the addition of the 17-kDa sheathprotein, but not by the 15 or 13-kDa sheath proteins (FIG. 12A). Thesheath proteins did not enhance the ALP activity of ST2 cells, althoughit was enhanced by the BMP-2 (FIG. 12B). The bioactivities of thesynthetic peptides were also tested using this cell culture system. TheC-1 peptide, which is at the C-terminus of the 17-kDa sheath protein andnot found on either the 15 or 13-kDa sheath proteins, also enhanced theALP activity of the HPDL cells. Some of the other peptides reduced theALP activity of HPDL cells, as did BMP-2. However, no synthesizedpeptide enhanced the ALP activity of ST2 cells (FIG. 12B).

Discussion

The CR promoting protein in the porcine enamel protein was determined tobe 17 kDa sheath protein using experimental bony cavities surgicallycreated in beagle dogs. The CR activity found in the 17 kDa sheathprotein was located in its C-terminal side peptide, which was not foundin the 15 kDa sheath protein.

In the cell culture system, the 17-kDa sheath protein increased the ALPactivity of HPDL cells. ALP activity is accepted as an indicator ofcytodifferentiation from a precursor to a mineralizing cell andacellular cementum formation (Beertsen et al., 1999).

The peptide synthesized based on the amino acid sequence of the 17-kDasheath protein also increased the ALP activity of the HPDL cells. Thisstrongly suggests that the 17-kDa sheath protein itself induces HPDLcytodifferentiation. The C-terminal region of the 17-kDa sheath proteinappears to be the true biologically active component in this fraction.The cytodifferentiation activity of this peptide links to CR activity inthe experimental bony cavities created along the roots of the canineteeth.

Example 3 Material & Methods

The peptides were synthesized based on the sequence of C-terminal sidepeptide of human sheath protein contains 66 amino acid residuesdifferent from the 40 residues of porcine extra C-terminal peptide.

Their sequences are SEQ ID NO: 3 (H-1), SEQ ID NO: 1 (H-2), SEQ ID NO: 2(H-3), SEQ ID NO: 4 (H-4) and SEQ ID NO: 5 (H-5). For searching theshortest peptide had cytodifferetiation activity of HPDL cells, SEQ IDNO: 26 (H-2-1), SEQ ID NO: 27 (H-3-1), SEQ ID NO: 28 (H-2-2), SEQ ID NO:29 (H-3-2), SEQ ID NO: 30 (H-2-3), SEQ ID NO: 31 (H-3-3) and SEQ ID NO:32 (H-2-4) were synthesized.

The bioactivities of these synthetic peptides were tested theircytodifferentiation activity of HPDL cells and ST2 cells bydetermination of increasing ALP inducing activity on cell culturesystem. When these peptides applied in cell culture system, theconcentration of their peptides was employed around 1 ng/ml. In the caseof TGF-□1, the concentration was 10 ng/ml.

Mineralization Activity

The HPDL cells were plated in 24-well plates at an initial density of1×10⁵ cells/well. After 24 h of incubation, the medium was replaced withgrowth medium containing 50 μM ascorbic acid, 10 mM β-glycerophosphate,and 10 nM 1α,25-dihydroxyvitamin D₃ (differentiation medium) and 1 μg/mlof samples. The medium was changed every 72 h and the cells weremaintained for 30 days. The biomineralization activity was examined bystaining with alizarin red S and measuring calcium content.

Results

When application of around 1 ng/ml of the H-2 and H-3 peptides, theyenhanced dose dependently the ALP activity of the HPDL cells (FIG. 13).The applications of these peptides enhanced the induction ofmineralization of HPDL cells in in vitro cell culture system for 30 daysalthough their mineralization levels were lower than that of TGF-β1application. The other peptides also enhanced the ALP activity of HPDLcells, although their activities are weaker than H-2 or H-3. Nosynthesized peptide enhanced the ALP activity of ST2 cells. All peptidessynthesized based on the sequences of H-2 and H-3 peptides increased ALPinducing activity of HPDL cells. It was confirmed LPG sequence was theshortest bioactive peptide enhanced cytodifferentiation of HPDL cells.

When TGF-β1 receptor inhibitor (SB431542) was applied into HPDL cellculture system, the ALP inducing activity of TGF-β1 was inhibiteddistinctly. However, ALP inducing activity increased by application ofsynthetic peptide was not inhibited by adding SB431542 (FIG. 14). It issuggested cytodifferentiation activity of synthetic peptides is inducedvia the other receptor different from TGF-β1 receptor.

Discussion

The apt concentration of TGF-β1 for increasing ALP inducing activity ofHPDL cells in cell culture system is around 10 ng/ml. Since themolecular weight of TGF-β1 is 25 kDa, its concentration is 0.4 nM/liter.Since average molecular weight of synthetic peptides is 1.5 kDa, adaptedconcentration of these peptides for increasing ALP inducing activity ofHPDL cells is 0.6 nM/liter. From these concentrations in cell culturesystem, the activity of these peptides is almost similar concentrationlevel as that of TGF-β1, growth factor.

When TGF-β1 receptor inhibitor (SB431542) was applied into HPDL cellculture system, the ALP inducing activity of TGF-β1 was inhibiteddistinctly. However, ALP inducing activity of HPDL cells increased byapplication of synthetic peptide was not inhibited by adding SB431542.It is suggested cytodifferentiation activity of synthetic peptides isinduced via the other receptor different from TGF-β1 receptor.

It is found that some of peptides derived from the C-terminal side ofhuman sheath protein promote the cytodifferentiation of HPDL cells toinduce mineralization, which links to CR promoting activity. It is alsofound the shortest peptide in bioactive peptides is LPG, amino acidtriplet.

Porcine enamel matrix proteins have been used already as EMDOGAIN® forclinical treatment of periodontal disease and periodontitis. At present,this remedy was preheated to avoid infection of E type virus. Thetreatment invalids the action of proteinases in the remedy and resultsto protect its CR promoting activity.

As shown in example 1, a considerable amount of amelogenin during thepreparation of fraction 1 causes the concentration of an activeingredient contained in EMDOGAIN®. The removal of abundant amelogeninfrom EMDOGAIN® involves in the improvement of present remedy.

The methods of removal of amelogenins from enamel proteins are gelfiltration in alkaline solution, ammonium sulfate fractionation andusage of insolubility of amelogenin in neutral solution at over roomtemperature. Therefore, the methods of removing the amelogenin fromenamel proteins are included in this invention.

Although we found CR promoting protein was 17 kDa sheath protein, atpresent, the fraction 1 separated by Sephadex G-100 gel filtration fromalkaline soluble fraction of newly formed secretory enamel showed thebest CR promoting activity

From example 3, the peptide contained LPG amino acid triplet will beuseful to regenerate periodontal ligament which is destroyed byperiodontal disease or periodontitis. The remedy for treatingperiodontal disease may be constructed with the peptide contained SEQ IDNO: 32, SEQ ID NO: 6 and/or SEQ ID NO: 7 (N-terminal side peptide ofamelogenin) and 1α,25-dihydroxyvitamin D₃. These peptide will besynthesized or made by recombinant.

REFERENCES

-   Bartlett J, Simmer J, Xue J, Margolis H, Moreno E: Molecular cloning    and mRNA tissue distribution of a novel matrix metalloproteinase    isolated from porcine enamel organ. Gene 183: 123-128, 1996.-   Beertsen W, VandenBos T, Everts V. Root development in mice lacking    functional tissue non-specific alkaline phosphatase gene: inhibition    of acellular cementum formation. J Dent Res 1999; 78: 1221-1229.-   Boyan B D, Weesner T C, Lohmann C H, Andreacchio D, Carnes D L, Dean    D D, Cochran D L, Schwartz Z. Porcine fetal enamel matrix derivative    enhances bone formatic induced by demineralized freeze dried bone    allograft in vivo. J Periodontol 2000; 71:1278-1286.-   Cerny R, Slaby I, Hammarström L, Wurtz T. A novel gene expressed in    rat ameloblasts codes for proteins with cell binding domains. J Bone    Miner Res 1996; 11: 883-891.-   Fukae M, Shimizu M: Studies on the proteins of developing bovine    enamel. Arch Oral Biol 1974; 19: 381-386.-   Fukae M, Tanabe T, Shimizu M: Proteolytic enzyme activity in porcine    immature enamel. Tsurumi U Dent J 1977; 3: 15-17.-   Fukae M, Tanabe T, Ijiri H, Shimizu M: Studies on porcine enamel    proteins: a possible original enamel protein. Tsurumi U Dent J 1980;    6: 87-94.-   Fukae M, Tanabe T, Shimizu M: Amino acid sequence of the main    component of porcine enamel proteins. Jpn J oral Biol 1983; 25    (Suppl.) 29.-   Fukae M, Tanabe T. Non-amelogenin components of porcine enamel in    the protein fraction free from the enamel crystals. Calcif Tissue    Int 1987a; 40:286-293.-   Fukae M, Tanabe T. ⁴⁵-labeled proteins found in porcine developing    dental enamel at an early stage of development. Adv Dent Res 1987b;    1(2): 261-266.-   Fukae M, Tanabe T, Uchida T, Yamakoshi Y, Shimizu M. Enamelins in    the newly formed bovine enamel. Calcif Tissue Int 1993; 53:257-261.-   Fukae M, Tanabe T, Murakami C, Dohi N, Uchida T, Shimizu M. Primary    structure of the porcine 89-kDa enamelin. Adv Dent Res 1996; 10:    111-118.-   Fukae M, Tanabe T, Uchida T, Lee S K, Ryu O H, Murakami C, Wakida K,    Simmer J P, Yamada Y, Bartlett J D: Enamelysin (matrix    metalloproteinase-20): localization in the developing tooth and    effects of pH and calcium on amelogenin hydrolysis. J Dent Res 77:    1580-1588, 1998.-   Fukae M, Tanabe T. Degradation of enamel matrix proteins in porcine    secretory enamel. Connective Tissue Res 1998; 39(1-3):    123-129(427-433).-   Fukae M, Kanazashi M, Nagano T, Tanabe T, Oida S, Gomi K. Porcine    sheath proteins show periodontal ligament regeneration activity. Eur    J Oral Sci 2006; in press.-   Gestrelius S, Andersson C, Lindström D, Hammarström L, Somerman M J.    In vitro studies on periodontal ligament cells and enamel matrix    derivative. J Clin Periodontol 1997; 24: 685-692.-   Gibson C, Yuan Z, Hall B, Longenecker G, Chen E, Thyagarajan T,    Sreenath T, Wright J T, Decker S, Piddington R Harrison G,    Kulkarni A. Amelogenin deficient mice display an amelogenesis    imperfecta phenotype. J Biol Chem 2001; 276:31871-31875.-   Hammarström L. Enamel matrix, cementum development and regeneration.    J Clin Periodontol 1997; 24: 658-668.-   Hammarström L, Heijl L, Gestrelius S. Periodontal regeneration in a    buccal dehiscence model in monkeys after application of matrix    proteins. J Clin Periodontol 1997; 24: 669-677.-   Heijl L. Periodontal regeneration with matrix derivative in one    human experimental defect. A case report. J Clin Periodontol 1997;    24: 693-696.-   Heijl L, Heden G, Svärdström G, Östgren A. Enamel matrix derivative    (EMDOGAIN®) in the treatment of intrabony periodontal defects. J    Clin Periodontol 1997; 24: 705-714.-   Hsu S M, Aine L R, Fanger H. A comparative study of the    perioxidase-antiperioxidase method and an avidin-biotin complex    method for studying the polypeptide hormones with radioimmunoassay    antibodies. Am J Clin Pathol 1981; 75:734-738.-   Hu C C, Bartlett J D, Zhang C H, Ryu O H, Simmer J p: Cloning cDNA    sequence, and alternative splicing of porcine amelogenin mRNAs. J    Dent Res 1996; 75: 1735-1741.-   Hu C-C, Fukae M, Uchida T, Qian Q, Zhang C H, Ryu O H, Tanabe T,    Yamakoshi Y, Murakami C, Dohi N, Shimizu M, Simmer J P. Sheathlin:    cloning, cDNA/polypeptide sequences, and immunolocalization of    porcine enamel sheath proteins. J Dent Res 1997a; 76: 648-657.-   Hu C-C, Fukae M, Uchida T, Qian Q, Zhang C H, Ryu O H, Tanabe T,    Yamakoshi Y, Murakami C, Dohi N, Shimizu M, Simmer J P. Cloning and    characterization of porcine enamelin mRNAs. J Dent Res 1997b; 76:    1720-1729.-   Ikawa T, Kakegawa A, Nagano T, Ando H, Yamakoshi Y, Tanabe T, Simmer    J P, Hu C C, Fuake M, Oida S. Porcine amelogenin is expressed from    the X and Y chromosomes. J Dent Res 2005; 84: 144-148.-   Iwata T, Morotome M, Tanabe T, Fukae M, Ishikawa I, Oida S, Noggin    blocks osteoinductive activity of porcine enamel extracts. J Dent    Res 2002; 81: 387-391.-   Kanazashi M, Gomi K, Tanabe T, Nagano T, Fukae M, Arai T.    Periodontal regeneration activity of protein fractions obtained from    the enamel matrix derivatives by the ammonium sulfate fractionation    (Japanese). Tsurumi Univ Dent J 2004; 30: 225-230.-   Kanazashi M, Gomi K, Nagano T, Tanabe T, Arai T, Fukae M. The 17-kDa    sheath protein in enamel proteins induces cementum regeneration in    experimental cavities created in a buccal dehiscence model of dogs.    J periodont Res 2006; in press-   Kawase T, Okuda K, Momose M, Kato Y, Yoshie H, Burns DM. Enamel    matrix derivative (EMDOGAIN®) rapidly stimulates phosphorylation of    the MAP kinase family and nuclear accumulation of smad2 in both oral    epithelial and fibroblastic human cells. J Periodontal Res 2001;    36:367-376.-   Krebsbach P H, Lee S K, Matsuki Y, Kozak C A, Yamada K M, Yamada Y.    Full-length sequence, localization, and chromosomal mapping of    ameloblastin: a novel tooth-specific gene. J Biol Chem 1996; 271:    4431-4435.-   Laemmli U K. Cleavage of structural proteins during the assembly of    the head of bacteriophage T4. Nature 1970; 227: 680-688.-   Murakami C, Dohi N, Fukae M, Tanabe T, Yamakoshi Y, Wakida K, Satoda    T, Takahashi O, Shimizu M, Ryu O H, Simmer J P, Uchida T.    Immunochemical and immunohistochemical study of 27 and 29 kDa    calcium binding proteins and related proteins in the porcine tooth    germ. Histochem Cell Biol 1997; 107: 485-494.-   Nagano T. Effects of fractionated porcine enamel proteins on    osteogenesis in human periodontal ligament (HPDL) cells in vitro    (Japanese). J Jpn Soc Periodontol 2003; 45: 384-393.

Nagano T, Oida S, Ando H, Gomi K, Arai T, Fukae M. Relative levels ofmRNA encoding enamel proteins in enamel organ epithelia andodontoblasts. J Dent Res 2003; 82:982-986.

-   Nagano T, Iwata T, Ogata Y, Tanabe T, Gomi K, Fukae M, Arai T,    Oida S. Effect of heat treatment on bioactivities of enamel matrix    derivatives in human periodontal ligament (HPDL) cells. J periodont    Res 2004; 39:249-256.-   Oida s, Nagano T, Yamakoshi Y, Ando H, Yamada M, Fukae M. Amelogenin    gene expression in porcine odontoblasts. J Den Res 2002; 81:    103-108.-   Shimizu M, Tanabe T, Fukae M: Proteolytic enzyme in porcine immature    enamel. J Dent Res 58B: 782-788, 1979.-   Shimizu M, Fukae M: Enamel proteins. In Mechanisms of Tooth Enamel    Formation (ed. by S. Suga): 125-141, Quitessence Publishing Co.    Inc., Tokyo, 1983.-   Shimokawa H, Ogata Y, Sasaki S, Sobel M E, McQuillan C I, Termine J    D, Young M F. Molecular cloning of bovine amelogenin cDNA. Adv Dent    Res 1987; 1: 293-297.-   Simmer J P, Fukae M, Tanabe T, Yamakoshi Y, Uchida T, Xue J,    Margolis H C, Shimizu M, DeHart B C, Hu C C, Bartlett J D.    Purification, characterization, and cloning of enamel matrix serine    proteinase 1. J Dent Res 1998; 77: 377-386.-   Snead M L, Lau E C, Zeichner-David M, Fincham A G, Woo S L C,    Slavkin H C. DNA sequence for cloned cDNA for murine amelogenin    reveals the amino acid sequence for enamel specific protein. Biochem    Biophys Res Commun 1985; 129:812-818.-   Somerman M J, Archer S Y, Imm G R, Foster R A. A comparative study    of human periodontal ligament cells and gingival fibroblasts in    vitro. J Dent Res 1988; 67: 66-70.-   Suzuki S, Nagano T, Yamakoshi Y, Gomi K, Arai T, Fukae M, Katagiri    T, Oida S. Enamel matrix derivative gel stimulates signal    transduction of BMP and TGF-β. J Dent Res 2005; 84:510-514.-   Tanabe T. Purification and characterization of proteolytic enzyme in    porcine immature enamel (Japanese). Tsurumi Univ Dent J 1984; 10:    443-452.-   Tanabe T, Aoba T, Moreno E C, Fukae M, Shimizu M. properties of    phosphorylated 32 kd nonamelogenin proteins isolated from porcine    secretory enamel. Calcif Tissue Int 1990; 46:205-215.-   Tanabe T, Fukae M, Uchida T, Shimizu M. The localization and    characterization of proteinases for the initial cleavage of porcine    amelogenin. Calcif Tissue Int 1992; 51: 213-217.-   Tanabe T, Fukae M, Shimizu M: Possible actions of metalloproteinases    found in porcine enamel in an early secretory stage. Adv Dent Res    10(2): 170-172, 1996.-   Uchida T, Tanabe T, Fukae M, Shimizu M, Yamada M, Miake K,    Kobayashi S. Immunochemical and immunohistochemical studies, using    antisera against 25 kDa amelogenin, 89 kDa enamelin and the 13-17    kDa nonamelogenins, on immature enamel of the pig and rat.    Histochemistry 1991; 96: 129-138.-   Uchida T, Fukae M, Tanabe T, Yamakoshi S, Satoda T, Murakami C,    Takahashi O, Shimizu M. Immunochemical and immunocytochemical study    of a 15 kDa non-amelogenin and related proteins in the porcine    immature enamel: proposal of a new group of enamel proteins ‘Sheath    Proteins’. Biomedical Research 1995; 16: 131-140.-   Yamakoshi Y, Tanabe T, Fukae M, Shimizu M. Porcine amelogenins.    Calcif Tissue Int 1994; 54: 69-75.-   Yamakoshi Y, Tanabe T, Oida S, Hu C-C, Simmer J P, Fukae M. Calcium    binding of enamel proteins and their derivatives with emphasis on    the calcium-binding domain of porcine sheathlin. Archives of Oral    Biology 2001; 46:1005-1014.-   Zetterström O, Andersson C, Eriksson L, Fredriksson A, Friskopp J,    Heden G, Jansson B, Lundgren T, Nilveus R, Olsson A, Renvert S,    Salonen L, Sjöström L, Winell A, Östgren A, Gestrelius S: Clinical    safety of enamel matrix derivative (EMDOGAIN®) in the treatment of    periodontal defects. J Clin Periodontol 1997; 24: 697-704.

1. A composition comprising an isolated polypeptide comprising SEQ IDNO: 11 wherein the amino acid at position 97 is not leucine.
 2. A methodof treatment for periodontal disease, comprising administering apharmaceutically effective amount of the composition of claim 1 to ahuman or mammal in need thereof.
 3. The method of claim 2, wherein theperiodontal disease is periodontitis.
 4. The method of claim 2, whereinthe treatment comprises periodontal tissue regeneration.
 5. The methodof claim 2, wherein the treatment comprises cementum regeneration. 6.The method of claim 2, wherein the treatment comprisescytodifferentiation of periodontal ligament cells.
 7. A compositioncomprising an isolated polypeptide consisting of SEQ ID NO:
 11. 8. Amethod of treatment for periodontal disease, comprising administering apharmaceutically effective amount of the composition of claim 7 to ahuman or mammal in need thereof.
 9. The method of claim 8, wherein theperiodontal disease is periodontitis.
 10. The method of claim 8, whereinthe treatment comprises periodontal tissue regeneration.
 11. The methodof claim 8, wherein the treatment comprises cementum regeneration. 12.The method of claim 8, wherein the treatment comprisescytodifferentiation of periodontal ligament cells.
 13. The compositionof claim 7, wherein the isolated polypeptide comprises a polypeptidesequence selected from the group consisting of polypeptide sequences SEQID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ IDNO: 13, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQID NO: 29, SEQ ID NO: 30 and SEQ ID NO:
 32. 14. A method of treatmentfor periodontal disease, comprising administering a pharmaceuticallyeffective amount of the composition of claim 13 to a human or mammal inneed thereof.
 15. The method of claim 14, wherein the periodontaldisease is periodontitis.
 16. The method of claim 14, wherein thetreatment comprises periodontal tissue regeneration.
 17. The method ofclaim 14, wherein the treatment comprises cementum regeneration.
 18. Themethod of claim 14, wherein the treatment comprises cytodifferentiationof periodontal ligament cells.